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SYNTHETIC ESSENTIALITY OF TDO2 IN APC-MUTATED COLORECTAL
CANCER
Rumi Lee, M.S.
Advisory Professor: Ronald DePinho, M.D.

Inactivation of the adenomatous polyposis coli (APC) tumor suppressor is
common genetic event across many cancers and serves a critical initiating
event in the majority of sporadic colorectal cancers (CRC). The WNT/APC
pathway remains an elusive target for cancer, prompting us to explore
orthogonal strategies to identify specific vulnerabilities for APC-deficient
CRC and other cancers. Using the concept of synthetic essentiality (SE), we
sought to identify essential effectors of APC deficiency with the goal of
expanding targetable vulnerabilities in CRC. We identified Tryptophan 2,3dioxygenase

2

(TDO2)

as

an

SE

gene

for

APC-deficient

cancers.

Mechanistically, APC loss results in TCF4/b-catenin-mediated activation of
TDO2 gene transcription. TDO2 in turn activates the Kyn-AhR pathway
which boosts glycolysis, promotes proliferation, and upregulates CXCL5
which recruits macrophages into the tumor microenvironment (TME). These
tumor-associated macrophages not only suppress anti-tumor immunity but
serve to support cancer cell survival via their secretion of GAS6 which
activates AXL in cancer cells, consistent with heterotypic symbiotic
signaling in the TME. Thus, APC-deficiency activates a TCF4-TDO2-AhR-
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CXCL5-GAS6-AXL circuit that impacts multiple cancer hallmarks via
autonomous

and

non-autonomous

mechanisms,

therapeutic targets for APC mutant cancers.

v

and

illuminates

new
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CHAPTER 1: INTRODUCTION

Chapter 1: Introduction
1.1 Adenomatous polyposis coli (APC)
1.1.1 Overview
The discovery of APC gene first initiated with the observation that
chromosome 5q21 band is deleted in a patient with Garner’s syndrome (Herrera et
al., 1986), which is a subtype of a subtype of familial adenomatous polyposis (FAP).
Family studies with FAP mapped the APC gene to 5q51 (Bodmer et al., 1987) and
the cloning and identification of APC gene were followed (Groden et al., 1991,
Kinzler et al., 1991). Human APC protein has 2,843 amino acid (aa) residues
(mouse APC: 2,842 aa) and is comprised of an oligomerization domain, an armadillo
repeat-domain, a basic domain, and binding domains for EB1 and disc large (DLG)
proteins (Fig. 1) (Fearnhead et al., 2001). The oligomerization domain contains the
heptad repeats that allow APC proteins to form helical homodimers (Joslyn et al.,
1993). The armadillo domain interacts with IQ-motif-containing GTPase activation
protein 1 (IQGAP1) and APC-Stimulated Guanine Nucleotide Exchange Factor
(ARHGEF4/29) and activates Cdc42 and Rac1, which in turn modulates cell
migration and adhesion by remodeling actin cytoskeleton (Kawasaki et al., 2000,
Watanabe et al., 2004).

Between the Armadillo domain and the basic domain,

multiple 15- and 20- residue repeats and serine-alanine-methionine-proline (SAMP)
repeats are located and are able to bind to β-catenin and Axin. Importantly, the
mutation cluster region (MCR) consists of several 20-aa repeat motifs is critical for βcatenin turnover and is prone to mutations (Xing et al., 2004, Kohler et al., 2008).
The basic region and EB1/DLG-binding domains interact with microtubules and
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regulate kinetochore functions, controlling chromosomal segregation (Morrison et al.,
1998, Tighe et al., 2004).

Figure 1: human APC protein structure
Human APC protein contains oligomerization domain and Armadillo repeats in its Nterminal and EB1- and DLG-binding domains in the C-terminal. β-catenin-binding
region interacts with β-catenin and mutations of APC mostly occur in the mutational
cluster region (MCR).
(Figure is reproduced from Aoki and Taketo, Adenomatous polyposis coli (APC): a
multi-functional tumor suppressor gene. Journal of Cell Science. 2007; 120, 33273335, with permission from Copyright Clearance Center)
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APC plays crucial roles in development and cellular homeostasis. In mice,
APC gene homozygous deletion leads to embryonic lethality at 5.5.d.p.c (Ishikawa et
al., 2003, Moser et al., 1995) and heterozygous knockout leads to defective thymic
development (Gounari et al., 2005) and FAP phenotype in the intestine (Oshima et
al., 1995). In addition, in vitro analysis showed that depletion of APC in human and
mouse cell lines resulted in chromosomal instability and dysregulated cell migration
(Dikovskaya et al., 2007, Kawasaki et al., 2003).

1.1.2 APC in Wnt signaling
Wnt signaling is highly conserved between species and plays a central role in
regulating tissue homeostasis and development. Canonical Wnt pathway controls
cellular processes through modulating the level of its key effector β-catenin.
Phosphorylation and ubiquitin-mediated degradation of β-catenin suppress the
activity of Wnt signaling and are regulated by β-catenin destruction complex. The
complex is comprised of AXIN, APC, casein kinase 1 (CK1), and glycogen synthase
kinase 3β (GSK3β) (Fig. 2). When Wnt ligand is absent, GSK3β and CK1
phosphorylate β-catenin N-terminal and consequently recruited the E3 ligase βtransducin

repeats-containing

proteins

(β-TrCP)

ubiquitinates

β-catenin.

Ubiquitinated β-catenin are subjected to proteasomal-mediated degradation.
Conversely, in the presence of Wnt ligand, it binds to the receptor Frizzled (FZD)
with co-receptor low-density lipoprotein-related protein 5/6 (LRP5/6) and recruits the
destruction complex to the membrane via a scaffold protein Dishevelled (DVL). The
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Figure 2: WNT signaling pathway
Schematics of inactive and active WNT signaling and its components.
(Figure is reproduced from Zhan, Rindtorff, and Boutros, Wnt signaling in cancer.
Oncogene. 2017; 36, 1461–1473, with permission from Copyright Clearance Center)
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interaction between DVL and AXIN elicits the dissociation of β-TrCP, resulting
in intact β-catenin. Accumulated β-catenin translocates to the nucleus and displaces
the Wnt repressor Groucho (Gro)/ transducin-like Enhancer of split (TLE) from key
Wnt transcription factors T cell factor (TCF)/lymphoid enhancer-binding factor (LEF)
and induces downstream Wnt target genes.

1.1.3 WNT signaling in colorectal cancers
Colorectal cancer (CRC) is the second leading cause of cancer-related death
in developed countries and responsible for more than 600,000 deaths globally each
year. The evolution of CRC from adenoma to adenocarcinoma and ultimately
invasive and metastatic disease is governed by the serial acquisition of signature
alterations that includes the loss of APC and p53 tumor suppressors and the
mutational activation of the KRAS oncogene (Orchard et al., 2013). Up-regulation of
the WNT pathway is frequently observed in the consensus molecular subtype 2
(CMS2) subtype of CRC (8), which accounts for nearly 40% of early-stage colorectal
tumors. Dysregulated Wnt signaling by mutations in key Wnt player genes leads to
dysregulated cell proliferation, survival, and ultimately promote tumorigenesis.

APC gene mutations
The APC gene functions as a tumor suppressor gene and loss of APC is the
critical initiating event which occurs in the vast majority (~90%) of sporadic CRC.
Inactivating mutations of the APC gene mostly occurs in the MCR region and include
deletion, single-base substitutions, and insertions resulting in truncated APC
6

proteins. It is estimated that above 75% reduction in APC protein level is sufficient to
form a polyp (Taketo, 2006). APC multiple intestinal neoplasia (APCMin) mice
harboring a heterozygous APC gene mutation at codon 850 develop adenomatous
polyps mostly in the small intestine (Su et al., 1992). Beyond initiation of neoplasia,
CRC mouse models have also established a role of APC in tumor maintenance
(Mao et al., 2015).
Germline mutations of APC gene predispose an individual to hereditary
cancer syndrome FAP. The most frequent APC gene loss-of-function germline
mutations occurs at codon 1,061 and 1,309, which are located in the MCR (Fig. 1)
(Fearnhead et al., 2001). The severity and the number of polyps in FAP are
correlated with where the mutations occurred; mutations within the MCR often cause
severe polyposis and patients with mutations located at the 5’ or 3’ of the APC gene
tend to show less severe FAP phenotype, attenuated adenomatous polyposis coli
syndrome (Fearon, 2011). Mutations in genes in DNA repair signaling such as MutL
Homolog 1 (MLH1) and Post-meiotic Segregation Homolog 2 (PMS2) in addition to
APC germline mutations are found in Turcot’s syndrome, which is characterized by
multiple

polyps

in

colon

with

higher

risk

of

CRC

and

brain

cancers

(medulloblastomas and glioblastoma) (Fearon, 2011). Interestingly, mutations at
codon 1,307I>K and 1,317E>Q, albeit modestly, lead to error-prone replication of
APC gene and predispose the loss of functional APC proteins (Sieber et al., 2003).
Multiple polymorphisms by SNPs in the APC genes have been identified (1458T>C,
4479G>A, 5268T>G) but the correlation with the variants to risk of developing FAP
or CRC remains to be determined (Chen et al., 2006).
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CRC tumors developed from FAP patients often exhibit loss-of heterozygosity
(LOH) of APC gene and the additional somatic mutations are associated with the
germline mutations in the MCR. Somatic mutations of APC gene in CRC are mostly
frameshift and nonsense mutations and they are usually clustered between codon
1,309 and 1,450 (Novellasdemunt et al., 2015). Mutated APC proteins lack the βcatenin and AXIN binding sites, resulting β-catenin accumulation and dysregulated
activation

of

Wnt

downstream

genes

including

C-MYC,

AXIN2,

matrix

metalloproteinase 7 (MMP-7), fibroblast growth factor 9 (FGF9) and CD44 (For an
extensive

list

of

Wnt

signaling

target

genes;

http://web.stanford.edu/group/nusselab/cgi-bin/wnt/).
Besides the mutations in the APC gene on the genomic level, multiple ways
to downregulate the expression of the APC gene in cancer cells have been
identified. Epigenetic silencing of APC gene by hypermethylation of promoter CpG
island, mostly in the 1A promoter region, is frequently shown in metastatic CRC and
is correlated with worse prognosis (Chen et al., 2005, van Engeland et al., 2011,
Liang et al., 2017). In addition, microRNA (miRNA) miR-494 is overexpressed in
CRC and negatively regulates the APC gene (Zhang et al., 2018) and long
intergenic non-coding RNAs (LncRNAs) CACS15 represses the expression of APC
via Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit (EZH2) in
ovarian cancer (Liu et al., 2019).
Other Wnt pathway genes mutations
CRC tumors often harbor loss of function mutations of multiple components of
Wnt signaling, leading to pathway dysregulation. Somatic mutations of CTNNB1
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gene, which encodes β-catenin protein, are rarely present in APC mutationharboring CRC but can be detected in subsets of CRCs without APC mutations
(Novellasdemunt et al., 2015, Morin et al., 2016). Mutations in the CTNNB1 gene
predominately occurs at the amino acid residues that are phosphorylated by CK1
and GSK3β in the N-terminal domain, resulting in accumulation of β-catenin (Liu et
al., 2002). Scaffold protein AXIN is encoded by AXIN1 and AXIN2 and their germline
(only found in AXIN2) and somatic mutations lead to uncontrolled activation of βcatenin (Fearon, 2011). The AXIN1 mutations are mostly missense mutations in
exon 5 and AXIN2 mutations are frequently C-terminal domain truncating mutations
in exon 7 (Mazzoni and Fearon, 2014). Hypermethylation of AXIN2 gene is also
found in CRC and shows association with initiating events of CRC (Koinuma et al.,
2006).
Ring finger protein 43 (RNF43) and Zinc And Ring Finger 3 (ZNRF3) are
ubiquitin ligases that are expressed in Lgr5+ intestinal stem cells and mediates
degradation of Wnt receptor FZD5 via endocytosis, acting as a negative regulator of
Wnt signaling (Koo et al., 2012). Hot spots for frameshift mutation in RNF43 gene
include codon R117 and G659 which are frequently found in CRC (Giannakis et al.,
2014). Interestingly, RNF43 mutations are mutually exclusive to APC mutations in
CRC and predominantly present in microsatellite instable-High (MSI-H) subtype of
CRC (Giannakis et al., 2014). One of the downstream targets of Wnt signaling Rspondin (RSPO) is a secreted protein and promotes endocytosis-mediated
internalization of RNF43/ZNRF3, allowing the Wnt receptor complex to activate the
downstream pathway (Fischer and Sigal, 2019, Hao et al., 2012). Genomic analysis
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of colon tumors and matched normal colon tissues revealed recurrent RSPO gene
fusion with Eukaryotic Translation Initiation Factor 3 Subunit E (EIF3E) or Protein
Tyrosine Phosphatase Receptor Type K (PTPRK), further activating Wnt signaling
(Seshagiri et al., 2012). Wilms tumor gene on the X chromosome (WTX)/FAM123B
is associated with Wilms tumor and functions as a tumor suppressor gene. WTX
forms the β-catenin destruction complex with APC, AXIN, β-TrCP2 and regulates
turnover of β-catenin (Major et al., 2007) and about 10% of CRC tumors harbor WTX
truncating mutations (TCGA, Firehose Legacy). In addition, epigenetic silencing by
promoter hypermethylation of Wnt negative regulators such as Dickkopf WNT
Signaling Pathway Inhibitor 1 (DKK1) (Rawson et al., 2011), Secreted frizzledrelated protein 1 (SFRP) (Suzuki et al., 2004), and WNT Inhibitory Factor 1 (WIF1)
(Taniguchi et al., 2005) have been identified in CRC.

1.1.4 Current cancer interventions for WNT/APC signaling
Since APC loss and upregulation of Wnt signaling occurs frequently across
many other cancer types, motivating efforts to understand more fully the function of
APC and its signaling pathway in governing specific hallmarks of cancer and to
illuminate therapeutic strategies targeting key pathway components or synthetic
lethal interactions. Given its importance in cancer, the therapeutic targeting of this
APC signaling cascade remains an important goal for cancer therapy. Currently, the
agents targeting WNT pathway include inhibition of WNT ligands, β-catenin
degrading complex, TCF/LEF, and Notch and Sonic Hedgehog signaling that
crosstalk with WNT. To date, these WNT targeting programs have yet to produce
meaningful clinical results.
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1.2 Synthetic Essentiality
The concept of synthetic lethality can be exploited to specifically target cancer
cells with alterations of tumor suppressor genes (TSGs). A set of genes is
considered ‘synthetic lethal’ when a combination of mutations in two genes leads to
cell death, whereas the cell is viable with loss of only one gene (9-11). However,
synthetic lethality screens can be limited to in vitro studies, which may not
recapitulate the in vivo biology of tumorigenesis and the diversity of human cancer
types. To overcome these constraints, DePinho lab developed a novel conceptual
frame ‘synthetic essentiality (SE)’ (12). SE genes are specifically crucial for growth
and survival of cancer with TSG deficiency (Fig. 3). These SE genes are rarely
mutated or deleted in tumors harboring mutant TSGs, creating mutual exclusive
patterns in human genomic data such as TCGA. We reasoned that these genes may
be essential for cancer-specific processes and would therefore be potential
therapeutic targets in cancers specifically harboring that tumor suppressor
deficiency.
To identify SE genes, genome-scale human datasets are analyzed for mutual
exclusiveness patterns for mutant TSGs (13). Expression profiles and clinical
databases can also be utilized to prioritize SE candidates. Functional validation of
putative SE genes involves in vitro assays and in vivo study (i.e. mouse models,
drug treatment). This approach uncovered the chromatin helicase DNA-binding
factor (CHD1) as an SE gene in PTEN-deleted cancers (14). CHD1 mutation profiles
in TCGA prostate cancer datasets exhibit a mutual exclusive pattern with PTEN
deletion. Deletion of PTEN leads to failure of CHD1 phosphorylation and its

11

subsequent ubiquitination, resulting accumulation of CHD1 and increased
expression of NF-kB target genes in prostate cancer cells. This study was followed
up by validating the importance of CHD1 mouse model. ICB study. Expanding the
concept to other TSGs may provide an opportunity for the discovery of targetable
vulnerabilities in cancers with undruggable gene mutations.

12

Figure 3: Conceptual frames to discover genetic context-specific cancer
vulnerabilities.
Synthetic essentiality (SE) describes an approach to identify synthetic essential
genes that are specifically crucial for growth and survival of cancer with tumor
suppressor gene deficiency.
(Figure is reproduced from Zhao and DePinho, Synthetic essentiality: Targeting
tumor suppressor deficiencies in cancer. Bioessays. 2017; 39, 8, 1700076 with
permission from Copyright Clearance Center)

13

1.3. Tryptophan 2,3-Dioxygenase
1.3.1 Overview
Tryptophan 2,3-Dioxygenase (TDO2) gene is located in chromosome 4q32.1.
As one of the enzymes that catalyze the first and rate-limiting step of the kynurenine
pathway, TDO2 gene was first mapped and cloned for behavior disorder study
(Comings et al., 1991) due to its functions in serotonin (5-hydroxytryptamine)
metabolism. Mutations in TDO2 gene are associated with pervasive developmental
disorder, Tic disorder, and multiple behavioral disorders in human (Comings et al.,
1991). TDO2 knockout mice exhibit increased tryptophan (Trp) and 5-HIAA (5hydroxyindoleacetic acid) plasma levels, anxiety-related behavior, and increased
neural progenitor cells in the hippocampus (Kanai et al., 2009).
Human TDO2 protein is a 406nt-long, heme-containing cytosolic protein and
is highly conserved in mouse (83.53% similar to human TDO2) (Ball et al., 2014).
The protein forms helixes with a flexible loop and is consisted of two substrate
binding domains and iron (heme-ligand) binding domain. Usually, TDO2 proteins are
tetrameric, and the loops are hypothesized to be induced by substrate binding,
especially L-Trp (Kanai et al., 2009). TDO2 protein is known to be interacting with
several other proteins, including ASMTL (Acetylserotonin O-Methyltransferase Like),
EIF4E (Eukaryotic translation initiation factor 4E), and PRMT6 (Protein Arginine
Methyltransferase 6) (Meng et al., 2014). Multiple sites have been identified for
TDO2 post-translational modification (PTM) in S23, S155, T200, T212, and S369, in
which are all conserved in mouse TDO2 as well (Hornbeck et al., 2015).
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Known regulation mechanisms of TDO2 expression can be categorized into
three groups: 1) Substrate (L-Trp) and co-factor activation 2) Heme-mediated
mechanism 3) Hormone induction. Specifically, expression of TDO2 by hormones is
induced when the hormones bind to their responsive elements including
glucocorticoid-responsive elements (GREs) for glucagon and estrogen response
elements (EREs) for estrogen (Ott et al., 2015).

1.3.2 Kynurenine pathway
Tryptophan (Trp) is an essential amino acid that has a variety of functions
within the cell, including synthesis of proteins, muscles, neurotransmitters (Cervenka
et al., 2017). Kynurenine pathway (KP) is the major tryptophan (Trp) catabolism
pathway in mammals and converts Trp into N- formylkynurenine (Kyn) (Fig. 4). This
metabolic pathway produces nicotinamide adenine dinucleotide (NAD+) and
nicotinamide from Trp in (intrahepatic) and outside the liver (extrahepatic), which
regulates systematic Trp levels and its metabolites in the body.
TDO2 and Indoleamine 2,3-dioxygenase (IDO) 1/2 mediate the first and rate-limiting
step of the KP. Evolutionally, IDO and TDO2 are not phylogenetically linked but they
are an example of functional convergence. In normal tissues, IDO is expressed in
tissues throughout the body, whereas TDO2 is predominantly expressed in the liver.
In a physiological setting, TDO2 almost solely regulates the intrahepatic Trp
conversion and IDO functions as an extrahepatic KP regulator. Interestingly, IDO
and TDO2 enzymes, especially in mammals, show differences in substrate
selectivity. IDO can be bound to wide range of indole-containing substrates but
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TDO2 is specific to the L-Trp enantiomer. Recent studies have shown that the nonredundant roles and differential expression of IDO and TDO2 in cancer cells, raising
the possibility of TDO2 inhibition as new therapeutic opportunity.
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Figure 4: Kynurenine pathway.
Tryptophan metabolism by kynurenine pathway. Red letters indicate enzymes
involved in the pathway. IDO, Indoleamine 2,3-dioxygenase; TDO2, Tryptophan 2,3dioxygenase; KYNU, Kynureninase; KATs, Kynurenine aminotransferases; KMO,
Kynurenine

3-monooxygenase;

3HAO,

3-hydroxyanthranilic

acid

oxygenase;

ACMSD, Aminocarboxymuconate-semialdehyde decarboxylase; QPRT, quinolinic
acid phosphoribosyltransferase.
(Figure is reproduced from Jones, Guillemin, and Brew, The Kynurenine Pathway in
Stem Cell Biology. International Journal of Tryptophan Research. 2013; 6 57–66
with permission from Copyright Clearance Center)
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1.3.3 Aryl hydrocarbon receptor signaling
The Aryl hydrocarbon receptor (AhR) belongs to the basic helix-loophelix/Per-Arnt-Sim (bHLH/PAS) transcription factor superfamily that responds to
environmental sensors (Gutierrez-Vazquez and Quintana, 2018), such as planar
aromatic (aryl) hydrocarbons and 2,3,7,8 -tetrachlorodibenzo-p-dioxin (TCDD). AhR
is activated by ligand binding and regulates xenobiotic-metabolizing enzymes
including CYP1A/B1/2 (Cytochrome P450 Family 1 Subfamily A/B Member 1/2) and
glutathione S-transferase (Andersson et al., 2002).
AhR harbors nuclear export and localization signal domains and can shuttle
nuclear-cytoplasmic compartments. When ligands are absent, AhR is cytoplasmlocalized and forms a complex with heat shock protein 90 (HSP90) and HBV Xassociated protein 2 (XAP2), which also known as aryl hydrocarbon receptor
interacting protein (AIP) (Fig. 5). Upon agonist binding, AhR nuclear translocator
(ARNT) displaces HSP90 from the AhR complex and translocates it to the nucleus.
The AhR complex binds to the dioxin-responsive element (DRE) and recruit coactivators (Fig. 5).
AhR ligands include indole metabolites, tryptophan metabolites, hemederived, and arachidonic acid metabolites (Gutierrez-Vazquez and Quintana, 2018).
Especially, tryptophan metabolites, as a physiological source of AhR ligands, are
majorly produced by KP in the cells and regulate AhR-mediated immune responses
and cellular signaling. AhR mediates a myriad of signaling pathways that are not
only critical for environmental danger sensing but also energy metabolism, cell
proliferation, metabolite synthesis/transport,
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Figure 5: AhR signaling
Regulation of AhR in the presence of AhR ligands. AHRR, AHR repressor; ARNT,
AHR nuclear translocator; XRE, xenobiotic response element.
(Figure is reproduced from Murray, Patterson and Perdew, Aryl hydrocarbon
receptor ligands in cancer: friend and foe. Nature Cancer Review. 2014; 14, 801-814
with permission from Copyright Clearance Center)
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and inflammation. In addition, AhR knockout mice exhibit slower growth, impaired
fertility, decreased liver weights, and cardiovascular defects, suggesting the roles of
AhR in development.

1.3.4 IDO/TDO2-Kyn-AhR signaling in cancer
It is well established that Trp catabolism plays a critical role in immune
suppression and cancer cell proliferation. TDO2 is highly expressed and
constitutively active in diverse cancers, such as glioblastoma, colorectal carcinoma,
and breast carcinoma (Pilotte et al., 2012). Up-regulated KP by increased TDO2
depletes Trp and accumulates Kyn, creating an immunosuppressive tumor
microenvironment (TME). Kyn acts as an agonist for AhR and differentiate naïve
CD4+ T helper (Th) cells to regulatory T cell (Tregs). In contrast, Kyn-AhR pathway
inhibits interleukin-17 (IL-17)-producing Th (Th17) cell differentiation (Prendergast,
2011).
Importantly, AhR directly regulates immune functions of different types of
immune cells, further modulating TME. AhR in CD8+ T cells, when bound to Kyn,
induces programmed cell death protein 1 (PD1) expression and mediates immune
evasion (Liu et al., 2018). Activation of AhR in tumor-associated macrophages
(TAMs) increases CCR2 expression and promotes infiltration into the tumor site
(Takenaka et al., 2019). AhR also regulates proliferation of Tregs and tolerogenic
myeloid cells, leading to immune resistance in glioblastoma (Campesato et al.,
2020).
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Besides the immune modulatory functions of AhR, it can also regulate cancer
cell intrinsic signaling and promote tumor initiation and progression. AhR activation
inhibits cell-cell adhesion, which leads to unhinged cell proliferation and deregulated
migration (Dietrich and Kaina, 2010). Interestingly, upon AhR ligand binding, Src and
EGFR pathways crosstalk with AhR downstream signaling to further activate cancer
cell proliferation and growth (Ye et al., 2018).

1.4. Tumor-associated macrophages
1.4.1 Overview
Monocyte precursors to macrophages can undergo polarization and
differentiation depending on the cellular microenvironment and express specific sets
of genes and phenotypic characteristics which determine their functions (Mantovani
et al., 2002). Discovery on the distinctive gene expression in macrophages when
treated with interleukin (IL)-4 (Nathan et al., 1983, Stein et al., 1992) initiated the
classification of macrophages based on their gene expression profiles; M1
(classically activated) and M2 (alternatively activated) (Mantovani et al., 2002). Most
well studied cytokines and chemokines that polarize monocytes include interferongamma (IFNγ) and lipopolysaccharide (LPS) for M1-type and IL-4 and IL-13 for M2type macrophages (Pathria et al., 2019). Once polarized, each population express
distinctive membrane receptors and effector molecules. M1 macrophages express
CD80, CD86, and opsonic receptors such as Fcγ-RI, II, III (CD16, CD32, CD64),
whereas M2 express CD163 and non-opsonic receptors such as Fcε-RII (CD23) and
mannose receptor (MR) (Brown et al., 2017). Classically activated M1 cells produce
pro-inflammatory cytokines, reactive oxygen/nitrogen species to promote Th1
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responses and mediate microbicidal functions. Alternatively activated M2 cells, in
contrast, produce arginase and anti-inflammatory cytokines, inhibiting tumor immune
resistance and regulating tumor progression (Mantovani et al., 2002). Due to the M2
cells’ pro-tumorigenic functions, they are also called tumor-associated macrophages
(TAMs). However, oversimplified functional grouping which is mostly based on
marker expression in the macrophages does not correctly explain the diverse and
reversible functions of immune cells. This issue prompted researchers to classify
macrophages into more detailed subtypes; M2a, M2b, M2c, and M2d (Roszer,
2015), based on the transcriptional changes upon environmental stimuli.
1.4.2 Tumor-associated macrophages in cancer
Tumor-associated macrophages (TAMs) can directly promote tumor growth
by secreting angiogenic factors (VEGF, PDGF), growth factors (EGF, FGF), and
cytokines (IFN-β) (Liu and Cao, 2015) (Fig. 6). The secreted factors from TAMs also
include Matrix metalloproteinases (MMPs) which are responsible for matrix
remodeling, metastasis, and recruitment of more monocytes. TGF-β and CCL2
signal fibroblasts to infiltrate TME and induce fibrosis within the tumor (Pathria et al.,
2019).
Importantly, TAMs regulate a variety of immune cell types that play critical
role in tumorigenesis by producing cytokines and chemokines and altering the target
cell functions or proliferation (Fig. 6). CCL18 from TAMs induces anergy of naïve T
cells and CCL22 and CCL17 recruit Th2 cells and Tregs into the tumor site, making
TME immunosuppressive (Liu and Cao, 2015).
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Figure 6: Roles of TAMs in tumor biology.
TAMs not only regulate various cell intrinsic pathways but also modulate immune
responses, promoting tumor progression and immune evasion.
(Figure is reproduced from Mantovani, Sozzani, Locati, Allavena and Sica.
Macrophage polarization: tumor-associated macrophages as a paradigm for
polarized M2 mononuclear phagocytes. TRENDS in Immunology. 2002; Vol.23
No.11 with permission from Copyright Clearance Center)
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1.4.3 Tumor associated macrophages-targeting interventions
Various ways to target TAMs have been tested in preclinical studies due to
multiple functions of TAMs in promoting tumorigenesis. Inhibition of colony
stimulating factor 1 receptor (CSF1R), one of the key TAM receptors, comprises the
viability of TAMs and this approach has shown promising preclinical results in
prostate and GBM cancer models (Stafford et al., 2016, Xu et al., 2013). Blocking
phenotype-specific receptors, such as CXCR4 and
CXCR7, to inhibit the cell recruitment showed improved radiation response in
multiple mouse tumor models (Domanska et al., 2014, Walters et al., 2014).
Antagonizing the secretory factors from TAMs with anti-VEGF and anti-CXCL12 has
been also investigated in the preclinical settings (Brown et al., 2017).

1.5 Growth arrest specific 6- Axl axis
1.5.1 Overview
Axl (UFO, ARK, TYRO7), along with Tyro3 (SKY, BRT, DTK, RSE, TIF) and Mer
(EYK, NTK, TYRO12), is a part of the TAM receptor tyrosine kinase (RTK) family
(Fig. 7) The TAM family members are transmembrane proteins which are consisted
of two immunoglobulin-like (IgL) extracellular domains which are connected to
tandem fibronectin type III repeats, transmembrane domain, and a cytoplasmic
portion that contains kinase domain. The TAM family is unusual RTKs because they
have no significant functions in embryonic developmental processes but have shown
their roles in mediating cellular signaling and pathological implications such as
proliferation, apoptosis, invasion, and immune responses. To the TAM RTKs, growth

24

Figure 7: TAM receptors and ligands.
TAM family members (Tyro3, Axl, Mer) and their domains are illustrated. Gas6 and
Protein S are most well studied ligands for TAM RTKs.

(Figure is reproduced from Lemke. Biology of the TAM Receptors. Cold Spring Harb
Perspect Biol 2013;5:a009076 with permission from Copyright Clearance Center)
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arrest specific 6 (Gas6) and Protein S are two major ligands, which are vitamin Kdependent proteins (Fig. 7). Protein S and Gas6 share high sequence homology and
have ability to activate the TAM family members. Gas6 was named after an
observation of its increased expression after NIH 3T3 cell serum starvation and
Protein S contains a thrombin sensitive cleavage site, which mediates the blood
coagulation signaling (Schneider et al., 1988).
Axl is ubiquitously expressed in the body and exhibits the highest affinity with
Gas6 (Wu et al., 2017). Upon binding of Gas6, Axl forms homodimers of another Axl
proteins but it also can form heterodimers with other TAM family members (Brown et
al., 2016). Once the receptor forms dimers, trans-autophosphorylation of tyrosine
residues occurs and initiate the cascade signaling activation including MAPK
signaling, PI3K pathway, and induction of SOCS proteins (Brown et al., 2016).
1.5.2 Gas6-Axl axis in Cancer
Broad downstream pathways that Axl exerts power on indicates the protumorigenic roles of Axl across all the molecular signaling. Axl promotes
proliferation, survival, invasion, and metastasis of cancer cells via JNK, PI3K,
Ras/ERK pathways (Wu et al., 2017). Axl and phosphorylated Axl are
overexpressed in multiple types of cancer and they are correlated with poor
prognosis, more advanced tumor stage, and resistance to anti-cancer therapy
(Pinato et al., 2016, Wimmel et al., 2001, Martinelli et al., 2015).

Small molecule

inhibitors for Axl have been developed and tested in preclinical breast cancer,
NSCLC, AML, and melanoma models. Specifically, R428 has shown high selectivity
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to Gas6/Axl complex and exhibited promising results, providing an insight to target
this universal tumor marker (Wu et al., 2017).
Gas6 itself can also promote tumorigenesis by educating monocytes to
become TAMs and invading tumor immune surveillance (Loges et al., 2010). Most
Gas6 present in the TME is macrophage-derived (Loges et al., 2010), suggesting a
synergetic relationship between macrophages and tumor cells. Studies also showed
that Gas6 can inhibit the anti-tumorigenic functions of NK cells (Paolino et al., 2014),
generating more immunosuppressive TME.
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Chapter 2: Materials and methods
Content of this chapter is partly based on the following articles:
Lee R, Li J, Chakravarti D, Chen P, Li J., Wu C, Jiang S, LaBella KA, Spring DJ,
Wang YA, Zhao D., DePinho RA., Synthetic Essentiality of TDO2 in APC-Mutated
Colorectal Cancer, Submitted

2.1 Mice
Five mice per cages were maintained under pathogen-free conditions. All
animal experiments were performed with the approval of MD Anderson Cancer
Center’s Institutional Animal Care and Use Committee (IACUC). NSG (NOD.CgPrkdcscid Il2rgtm1Wjl/SzJ), C57BL/6J, and BALB/cJ mice were purchased from
Jackson laboratory (Stock No: 005557, 000664, 000651). Colorectal orthotopic
xenograft tumor models were established by following protocol (Tseng et al., 2007,
JoVE). After orthotopic injection of cells, mice that exhibited successful tumor
formation were randomized before starting Dox, antibody, or inhibitor treatment for
each cell line. Sample size was determined based on previous similar experiments
performed in our lab.

2.2 Cell Culture
The CRC cell lines MC38 and its isogenic cells, BMDM and 293T cells were
cultured in Dulbecco's Modified Eagle's Medium (DMEM). CCD-841-CoN, RKO, HT29 and LS180 cells were cultured in Eagle's Minimum Essential Medium (EMEM).
HT-29 cells were cultured in McCoy’s 5A medium. DLD-1, CT26, and Raw264.7
macrophage cell line was cultured in RPMI 1640 medium (RPMI). All cell lines were
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cultured in indicated medium containing 10% Tet System Approved FBS (Clontech)
and 100U/ml ampicillin/penicillin. All human cell lines have been validated through
fingerprinting by the MD Anderson Cell Line Core Facility. All cells were confirmed to
be mycoplasma-free and maintained at 37 °C and 5% CO2. BMDMs from C57BL/6
mice were cultured as previously described (Chen et al., 2017). Conditioned media
were collected from treated or untreated cells as indicated after culturing for 24 h in
FBS-free culture medium.

2.3 CRISPR-Cas9 Transfection
sgRNA plasmids targeting human APC gene (sc-400374) were purchased from
Santa Cruz Biotechnology. For mouse APC gene, a sgRNA target sequence of
TTGAGCGTAGTTTCACTCCG was cloned into pCas-Guide-EF1a-GFP plasmids
(Origene Technologies, Inc.). Human RKO and mouse MC38 cells were maintained
in 6-well plates to a 70-80% confluency in culture media supplemented with 10%
heat-inactivated FBS and 100U/ml ampicillin/penicillin. The plasmids with sgRNA
were transiently transfected into using Lipofectamine 2000 according to the
manufactory protocol. Cells were harvested 72 h later, and GFP-positive cells were
sorted into each well of a 96-well plate as single cell by flow cytometry. At day 10
after cell sorting, the grown cell colonies were expanded in 24-well plates. The
knock-out of APC gene in each colony was confirmed by RT-PCR and western blot
for APC and β-catenin.

2.4 Mouse Colon Organoid Culture and Genome Engineering

30

To isolate colonic crypts for organoid culture, a 2 cm piece of distal colon was
incubated in PBS containing 5mM EDTA 0.2% FBS at 4°C for 45 min on a
shaker. Incubated colon pieces were shaken vigorously to release crypts. Crypts
were washed and spun down sequentially at 300g, 200g, and 100g to enrich for
intact crypts. Crypts were resuspended in Matrigel and plated in 24-well plates
containing 50uL Matrigel per well. 500uL of organoid culture media containing
Wnt3a, R-spondin, Noggin, and EGF was added and changed every 2 days.
Knockout of Apc was performed via transient transfection of a plasmid
expressing Cas9 and a sgRNA targeting Apc (Apc sgRNA-LentiCRISPRv2; sgRNA
sequence: APC-G0-1 – CGCTTGTCTAGATAAGCACG). Apc-/- organoids were
selected by removal of Wnt and R-spondin from the media.

2.5 Mouse APCmin Organoids
Intestinal polyps from a 18 week-old male APCmin mouse were harvested
and the cut tissue were treated with complete chelating solution containing 30mM
EDTA for 30 min at 4ºC. The tissue pieces were then pipetted gently to dissociate
the crypts. These crypts were then seeded in Matrigel (Corning) in the presence of
high WNT organoid media in the presence of ROCK inhibitor Y-27632 (STEMCELL
Technologies Inc.) for 7-10 days.

2.6 Human Samples
Tissue microarrays (TMA) were obtained from Department of pathology at the
University of Texas MD Anderson Cancer Center. The studies related to human
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specimens were approved by the MD Anderson Institutional Review Board under
protocol Lab09-0373.

2.7 Mutual exclusivity analysis
Mutual exclusivity analysis was performed by the method of Zhao et al., 2017.
described by the authors as follows: For the analysis of mutual exclusiveness for
APC in colorectal cancer, the genetic alteration of 220 TCGA CRC samples with
copy number alterations and sequencing data were downloaded from cBioPortal
(https://www.cbioportal.org/) ; the gene expression dataset was downloaded from
Broad

GDAC

website

(

http://gdac.broadinstitute.org/runs/stddata__2016_01_28/data/COAD/20160128/);
The detailed method about how to estimate the mutation exclusivity was previously
described in (Zhao et al., 2017). Briefly, the rank score (odds ratio score) was
calculated to indicate mutual exclusiveness between gene A and gene B deletion.
The mean values of gene B expression in all 220 samples and that in gene A
deleted samples were calculated and analyzed with student t-test. For APC
mutations in CRC datasets, only deletion and mutations with known significance
(annotated by OncoKB) cases were considered.

2.8 TCGA data computational analysis
For analysis of human CRC and BRCA data, we retrieved the gene
expression and copy number data of TCGA datasets or other available datasets
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from cBioPortal: https://www.cbioportal.org/. Correlation analysis of TDO2, AhR, and
CYP1B1 expression in CRC was performed with R2 platform: https://r2.amc.nl/.

2.9 Gene stable shRNA/siRNA knockdown and inducible shRNA knockdown
Mission shRNA hairpins targeting mouse TDO, AhR, and Gas6 were
purchased from Santa Cruz and GIPZ shRNA hairpins targeting human TDO were
purchased from Horizon. For inducible TDO2 knockdown, SMARTvector Inducible
Lentiviral shRNA for mouse TDO2 was purchased from Horizon. The sequences that
decreased mRNA and/or protein levels by >80% were chosen. For in vivo
bioluminescence imaging, luciferase vector EF1-RFP-T2A-Luciferase (system
Biosciences) was used.
Lentiviral infection was performed by the method of Zhao et al. (Zhao et al.,
2017) described by the authors as follows: Recombinant lentiviral particles were
produced by transient transfection of plasmids into HEK293T cells. In brief, 8 µg of
the shRNA plasmid, 4 µg of the psPAX2 plasmid, and 2 µg of the pMD2.G plasmid
were transfected using Lipofectamine 3000 into 293T cells plated in 100-mm dishes.
Viral supernatant was collected 48 h and 72 h after transfection and filtered. Cells
were infected twice in 48 h with viral supernatant containing 8 µg/ml polybrene, and
then selected using 2 µg/ml puromycin and tested the expression TDO2, AhR, Gas6,
and TCF4 by RT-qPCR. The following shRNA sequences were used.

Human shTDO2 #3: NM_005651: 5’-AATCTGATTCATCACTGCT-3’,
Human shTDO2 #6: NM_005651: 5’-AAATCTACAAATACCTTGT-3’,
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Mouse shTDO2 #2: NM_019911: 5’CGGCCAAAGATGAATCCGATCATTCTCGAGA
ATGATCGGATTCATCTTTGGTTTTTG-3’,
Mouse shTDO2 #4: NM_019911: 5’GGGCGCAAGAACTTCAGAGTGAACTCGAGTT
CACTCTGAAGTTCTTGCGCTTTTTG-3’,
Mouse ishTDO2 #3: NM_019911.2: 5’-GGATTTAATTTCTGGGGAA-3’,
Mouse shAhR #1: NM_013464: 5’CGGCATCGACATAACGGACGAAATCTCGAGAT
TTCGTCCGTTATGTCGATGTTTTTG-3’,
Mouse shAhR #2: NM_013464: 5’GTACCGGGTCAAGCCTGTTAGCTATATTCTCGA
GAATATAGCTAACAGGCTTGACTTTTTTG-3’,
Mouse shGas6 #1: NM_019521: 5’CCGGCCTGGCACTGATGGAAATCAACTCGAG
TTGATTTCCATCAGTGCCAGGTTTTTG -3’,
Mouse shGas6 #2: NM_019521: 5’CCGGGCTGTAATGAAGATCGCGGTACTCGAG
TACCGCGATCTTCATTACAGCTTTTTG -3’.
Human shTCF4 #1: NM_030756: 5’CCGGCCTTTCACTTCCTCCGATTACCTCGAGGTAATCGGAGGAAGTGAAA
GGTTTTTG -3’,
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Human shTCF4 #2: NM_030756: 5’CCGGAGAGAAGAGCAAGCGAAATACCTCGAGGTATTTCGCTTGCTCTTCT
CTTTTTTG -3’,

For siRNA experiments, Lipofectamine RNAiMAX Transfection Reagent
(Thermo Fisher, 13778030) was used and the assay was performed by following
manufacturer’s protocol. Transfected cells were maintained for three days and
knockdown efficiency for TCF4 was measured by western blotting. The following
siRNAs (Sigma-Aldrich) were used.

Human siTCF4 #1: NM_030756: SASI_Hs01_00197690
Human siTCF4 #2: NM_030756: SASI_Hs01_00197691
Human siTCF4 #3: NM_030756: SASI_Hs01_00197692
Mouse siTCF4 #1: NM_009333: SASI_Mm01_00142189
Mouse siTCF4 #2: NM_009333: SASI_Mm02_00315891
Mouse siTCF4 #3: NM_009333: SASI_Mm01_00142190

2.10 Western blot
Cell lysates were prepared with RIPA lysis buffer (Roche) with Halt™
Protease and Phosphatase Inhibitor Single-Use Cocktail (Thermo, 78442).
Immunoblotting was performed following standard protocol. Antibodies were
purchased from the indicated companies, including β-actin, tubulin, vinculin, TDO2,
β-catenin, TCF4, cleaved Caspase-3.

35

2.11 Hairpin-resistant ORF and cytokine ORF expression
To construct hairpin-resistant hTDO2 ORF expression vector to shTDO2 #3,
site-directed mutagenesis was performed with human TDO2 ORF gene in
pcDNA3.1+/C-(k)DYK vector (GenScript, OHu09674D). Nucleotide mutation was
targeted for 1) 1272 T to C, 2)1275 T to C, 3) 1278 A to G, 4) 1281 A to G and no
amino acid was altered. Mutated TDO2 ORF gene insert was subcloned into
PS100102 (pLenti-C-mGFP-P2A-BSD Tagged Cloning Vector (Origene, PS10094).
For mutagenesis, following primers were used:

F: 5’-CCTACTTCAGCAGCGACGAGTCGGATTAAAATCG-3’
R: 5’-CGATTTTAATCCGACTCGTCGCTGCTGAAGTAGG-3’

Lentiviral ORF expressing vectors for blank, CXCL5, CXCL7, and CSF3 were
purchased from ABM (LV587, LV407122, LV395200, LV455866).

2.12 Luciferase assay
HEK 293T cells were seeded in each well of 24-well plates and transfected
with luciferase reporter vectors of pGL3-Basic (Promega, E1751), pGL3-hTDO2
promoter, or pGL3-hTDO2 promoter with a mutated TCF4 binding site with pRL
Renilla Luciferase Control Reporter Vector (Promega, E2261) and pLV-beta-catenin
DN90 (Adddgene, 36985) using Lipofectamine 2000 reagent (Thermo, 11668019).
pcDNA/Myc DeltaN TCF4 expression vector (Addgene,16513) was transfected to
express dominant negative form of TCF4. Luciferase activity was measured with
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Dual-Luciferase reagent (Promega, E1910) and assays were performed according to
the manufacturer's instructions.

2.13 Cytokine array and phospho-RTK array
For cytokine array, CRC orthotopic tumors established with ishTDO2 APCWT

and

APC-KO

MC38

cells

were

incubated

in

RIPA

buffer

with

protease/phosphatase inhibitor cocktail and homogenized. Cytokine array was
performed with mCytokine Array Kit, Panel A (R&D Systems, ARY006) and the
manufacturer’s protocol was followed. For phospho-RTK array, ishTDO2 APC-WT
and APC-KO MC38 cells were treated with dox for 48hr and the lysates were used
for the array. Assays were performed according to the manufacturer's instructions for
mPhos RTK Array Kit (R&D Systems, ARY014).

2.14 Immunohistochemistry and immunofluorescence
Immunohistochemistry was performed using standard protocol as we
previously described (19). Antibodies specific to TDO2, AhR, β-catenin, Ki67,
Cleaved caspase-3, F4/80, CD163, CD206, p-AXL, EpCam were used in this study.
For immunofluorescence nuclei staining, DAPI was used. The human and mouse
tumor tissue sections were reviewed and scored.

2.15 Migration assay
Assay was performed by the method of Chen et al. (Chen et al., 2019)
described by the authors as follows: Macrophages (1 × 104 for Raw264.7 and
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BMDM) were suspended in serum-free culture medium and seeded into 24-well
Transwell inserts (5.0 µm). Medium with indicated factors or conditioned media was
added to the remaining receiver wells. After 24 h, the migrated macrophages were
fixed and stained with crystal violet (0.05%, sigma), and then counted with ImageJ.

2.16 Colony formation assay
Colorectal cancer cell proliferation in vitro was assayed through colony
formation. 1 × 103 cells were seeded in each well of 6-well plates and cultured for 57 days. At the end point, cells were fixed and stained with 0.5% crystal violet in 25%
methanol for 1 hr. These experiments were performed in triplicate.

2.17 TDO2 inhibitor and Epacadostat treatement
The structure of the TDO2 inhibitor (PF06845102/EOS20080) was referenced
from Schramme et al., 2020 study (Schramme et al., 2020). Institute of Applied
Cancer Science (IACS) at MDACC synthesized the TDO2 inhibitor according to the
compound

structure.

TDO2

inhibitor

(200mg/kg)

was

dissolved

in

0.5%

hydroxypropyl methylcellulose (HPMC) before each injection and administrated
orally twice daily by oral gavage. For Epacadostat treatment, the compound
dissolved in 10% DMSO was further diluted in 90% corn oil and administrated orally
twice daily at 100mg/kg by oral gavage.

2.18 Mass Cytometry (CyTOF)
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Mutual exclusivity analysis was performed by the method of Liao et al. (Liao
et al., 2019) described by the authors as follows: Briefly tumors were digested and
single cells blocked with FcR were incubated with surface antibody. Cells were then
incubated with Cell-ID Cisplatin (Fluidigm, Cat# 201064) and permeabilized for
FOXP3 intracellular staining. For nuclei staining, cells were incubated with Cell-ID
Intercalator-Ir (Fluidigm, Cat #201192A) while fixing. Samples were analyzed with a
CyTOF instrument (Fluidigm) in the Flow Cytometry and Cellular Imaging Core
Facility at MD Anderson Cancer Center. Cell numbers and percentages of each cell
populations were analyzed with FlowJo (Tree Star) and GraphPad Prism 6 software.
CyTOF data were visualized using a dimensionality reduction method viSNE (Amir
et al., 2013), which was implemented using the Cytobank (Chen and Kotecha,
2014).

2.19 Kyn, 2-DG uptake and lactate secretion measurement
Kyn concentration was measured by following manufacturer’s protocol for Kyn
ELISA measurement kit (ImmuSmol, BA-E-2200). 2-DG uptake assay was
performed according to manufacturer’s protocol for 2-Deoxyglucose Uptake
measurement kit (Cosmo Bio, CSR-OKP-PMG-K01TE). For secreted lactate
measurement, Lactate Colorimetric/Fluorometric Assay Kit (BioVision, 10186-852)
was used and assay was performed by following manufacturer’s protocol.

2.20 LC-MS/MS-Based Targeted Metabolomics
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Media from cultured cells were harvested and quickly put them into dry ice or
-80°C freezer. Cells were washed twice with ice-cold PBS and snap-frozen by
putting the flasks on liquid nitrogen. Frozen cells were scraped 1.

into 1mL of -

70°C-cooled 80% methanol for collection and quickly stored at -80°C. LC-MS/MS
analyses were performed on an AB SCIEX QTRAP 6500 LC-MS/MS system at
Pharmacology Core of Karmanos Cancer Institute. Analyst 1.6 software was used
for system control and data acquisition, and MultiQuant 3.0 software was used for
data

processing

and

quantitation.

For

statistical

analysis,

Metaboanalyst

(https://www.metaboanalyst.ca/) was used.

2.21 ChIP–sequencing and ChIP-PCR
ChIP was performed by the method of Chen et al. (Chen et al., 2019)
described by the authors as follows: Chromatin from PFA-fixed cells were crosslinked with 1% PFA and then reactions were quenched using 0.125 M Glycine. Cells
were lysed with ChIP lysis buffer [10 mM Tris-HCl (pH 8.0), 140 mM NaCl, 1 mM
EDTA (pH 8.0), 1% Triton X-100, 0.2% SDS and 0.1% deoxycholic acid] for 30 min
on ice. Chromatin fragmentation was performed using a Diagenode BioruptorPico
sonicator (30 s on and 30 s off, 45 cycles) and incubated with the appropriate
mixture of antibody and Dynabeads (Life Technologies) overnight. Immune
complexes were washed with RIPA buffer (three times), once with RIPA-500 (RIPA
with 500 mM NaCl), and once with LiCl wash buffer [10 mM Tris-HCl (pH 8.0), 1 mM
EDTA (pH 8.0), 250 mM LiCl, 0.5% NP-40 and 0.5% deoxycholic acid]. Elution and
reverse-crosslinking were performed in direct elution buffer [10 mM Tris-Cl (pH 8.0),
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5 mM EDTA, 300 mM NaCl, 0.5% SDS] containing proteinase K (20 mg/ml) at 65 °C
overnight. Eluted DNA was purified using AMPure beads (Beckman-Coulter), which
then was used to generate libraries using NEBNext Ultra DNA Library kit (E7370), or
to perform qPCR. Sequencing was performed using an Illumina HiSeq 2500
instrument to generate dataset.

2.22 mRNA expression analysis, microarray and RNA sequencing
Cells were pelleted, and RNA was isolated with RNeasy Mini Kit (Qiagen,
74104). RNA was reverse-transcribed into cDNA by following SuperScript™ III FirstStrand Synthesis SuperMix (Invitrogen, 18080400). qRT-PCR was performed using
SYBR Green PCR Master Mix (Thermo Fisher Scientific) in a 7500 Fast Real-Time
PCR Machine (Applied Biosystems). qRT-PCR primers are listed in Supplementary
Table. The expression of each gene was normalized by that of GAPDH or Actin. For
microarray, tumors established with ishTDO2 APC-WT and APC-KO MC38 cells
was harvested (biological triplicates for control and APC-KO MC38 tumors). RNAs
were isolated using Trizol (Invitrogen, 15596-026) and further purified with the
RNeasy Mini Kit. Samples were analyzed at the MD Anderson Microarray Core
facility using the GeneChip Mouse Clariom D array (Affymetrix) to generate dataset.
Genes that were differentially expressed between control and APC-depleted MC38
cells were subjected to gene set enrichment analysis (GSEA). For RNA sequencing,
RNAs were isolated from ishTDO2 APC-WT and APC-KO MC38 cells with and
without Dox treatment were harvested (biological triplicates per group) using the
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RNeasy Mini Kit. Illumina TrueSeq CHIP library was used for Illumina Next Seq 500
Sequencing.

2.23 Quantification and statistical analysis
All statistical analyses were performed with Student's t-test and represented
as mean ± SD. The analysis of TAM IHC staining for the correlation among nuclear
b-catenin, TDO2, and CD163 was performed using the chi-squared test. Mouse
survival analysis was performed using Log-rank (Mantel-Cox) test (GraphPad Prism
9). The p values were designated as: *, p<0.05; **, p<0.01 and ***, p<0.001; n.s.
non-significant (p>0.05).
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Chapter 3: Identification of synthetic essential genes for APC mutations
Content of this chapter is partly based on the following manuscript:
Lee R, Li J, Chakravarti D, Chen P, Li J., Wu C, Jiang S, LaBella KA, Spring DJ,
Wang YA, Zhao D., DePinho RA., Synthetic Essentiality of TDO2 in APC-Mutated
Colorectal Cancer, Submitted

3.1 Introduction and rationale
Expanding the synthetic essentiality (SE) concept to other tumor suppressor
genes may provide an opportunity to discover targetable cancer vulnerabilities with
undruggable gene mutations. We embarked on an effort to expand this approach to
other tumor suppressors and given the significance of the APC gene in regulating
CRC tumorigenesis and its prevalent mutation rate in CRC and other cancers. We
first screened The Cancer Genome Atlas (TCGA) database and genome scale lossof-function screening data for genes that are retained in the context of APC loss-offunction mutations.

3.2 Results
3.2.1 Identification of TDO2 as a downstream effector for APC deficiency in
cancer
To identify synthetic essential effectors of APC-deficiency in CRC, we first
searched for genes showing mutually exclusive mutation/deletion patterns with APC
mutations or deletion cases in CRC TCGA database. Due to the gatekeeper
functions of APC gene mutations in CRC initiation process, a majority of CRC cases
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(~70%) harbor APC deletion or loss-of-function mutations. To overcome the
limitation that only a small fraction of CRC cases are intact for APC, we conducted a
pan-cancer analysis which showed consistent retention of TDO2 in APC
deleted/mutated cancers including CRC, breast cancer, prostate cancer, lung
cancer, head and neck squamous cell carcinoma and sarcoma (Fig. 7). We also
included the mutation cases of CTNNB1, which encodes b-catenin that functions as
a downstream effector of APC/WNT signaling. We found that TDO2 showed mutual
exclusive patterns to CTNNB1 as well, which further showing the mutual exclusivity
of TDO2 to WNT signaling.
Recognizing the limited sample size and low frequency of these genomic
events, we triangulated these genomic results with (i) hits from genome wide loss-offunction screens designed to identify genes that are consistently retained in cancer
cells bearing APC loss-of-function mutations (Rosenbluh et al., 2012) and (ii)
unbiased transcriptomic analyses to identify genes with positive correlations of WNT
pathway

activation

signature

(Van

der

Flier

et

al.,

2007)

and

HALLMARK_WNT_BETA_CATENIN_SIGNALING (Subramanian et al., 2005).
These intersections yielded 5 potential SE genes for APC-deficient tumors (TDO2,
C3, MAFB, CAB39L, PPFIA2) with TDO2 as the top hit (Fig. 8A).
We performed a similar analysis using the same datasets with statistical
cutoffs for each dataset and TDO2 is the highest ranked gene identified by the
triangulation Specifically, triangulation identified 5 genes (TDO2, C3, MAFB,
CAB39L, PPFIA2) with cutoffs of p<0.01 and FDR<=0.01; and identified 13 genes
(IRS1, TDO2, C3, MAFB, CAB39L, PPFIA2, SORCS2, COL6A3, CPZ, CTSO,
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GAMT, GLRB, SPOCK3) with less stringent cutoffs of p<0.05 and FDR<=0.05.
When we applied a FDR cutoff (FDR<0.3) in addition to the p value for RNAi dataset
narrowed down the RNAi dataset number to 81 and triangulation with WNT
signature correlation and mutual exclusivity datasets identified only TDO2.
Finally, we performed similar in silico analysis with TCGA breast cancer
dataset (BRCA) to evaluate whether synthetic essential roles of TDO2 are CRCspecific or they are applicable to other types of cancer. Similar to the CRC analysis,
we triangulated the genome-scale loss-of-function screen data with (i) TCGA BRCA
mutual exclusive dataset for APC/CTNNB1 genes (ii) TCGA BRCA genes that
exhibit higher expression in APC/CTNNB1-mutant BRCA tumors compared to
APC/CTNNB1-WT BRCA. This analysis revealed three potential SE genes for
APC/CTNNB1-mutant BRCA (TDO2, YES1, UCHL5), further strengthens our
findings of the correlation of TDO2 with WNT signaling and specific essentiality in
APC-mutant tumors (Fig. 9).
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Colorectal Adenocarcinoma (TCGA, Provisional) n=220
TDO2: 1.4%
CTNNB1: 1.8%
APC: 70%

TDO2: 1.7%

Breast Invasive Carcinoma
(TCGA, Provisional) n=973

CTNNB1: 0.4%
APC: 1.2%

TDO2: 1.1%
CTNNB1: 1.4%
APC: 2.6%

TDO2: 1.4%
CTNNB1: 1.2%
APC: 1.6%

TDO2: 2.8%
CTNNB1: 4%
APC: 5%

Pan-Lung Cancer
(TCGA, Nat Genet 2016) n=1144

Prostate Adenocarcinoma
(MSKCC/DFCI, Nature Genet 2018) n=1013

TDO2: 3%
CTNNB1: 2.1%
APC: 5%

Sarcoma
(TCGA, Provisional) n=243

Head and Neck Squamous Cell Carcinoma
(TCGA, Provisional) n=504

Figure 7: Mutual exclusive patterns of TDO2 and APC/CTNNB1 in TCGA
database of multiple cancer types.
The percentages of alteration in each gene are indicated.
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Figure 8: TDO2 as a synthetic essential gene for mutant APC gene in CRC.
(A) Venn diagram representing synthetic essential gene analysis using three
different datasets identified TDO2 as a top potential SE gene for mutant APC gene.
(B) Representation of clustering of TCGA COAD and READ dataset based on the
expression of WNT signature genes (Van der Flier et al., 2007). APC mutation status
is shown on the bottom. (C) Expression of WNT signature genes are correlated with
TDO2 expression in TCGA CRC (COAD + READ, Provisional) patient samples
(n=433). ****P<0.0001 (D) Representation of clustering of TCGA COAD and READ
dataset

based

on

the

expression

of

hallmark

WNT

gene

sets

(HALLMARK_WNT_BETA_CATENIN_SIGNALING). (E) Expression of hallmark
WNT genes are correlated with TDO2 expression in TCGA CRC (COAD + READ,
Provisional) patient samples (n=433). ****P<0.0001
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Figure 9: TDO2 as a synthetic essential gene for mutant APC/CTNNB1 gene in
BRCA.
Venn diagram representing synthetic essential gene analysis using three different
datasets identified TDO2 as one of the potential SE genes for mutant APC/CTNNB1
gene in BRCA.
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3.2.2 TDO2 expression is correlated with WNT activation in CRC
We performed expression analysis using two different WNT signature gene
sets: one from GSEA pathway hallmark geneset and the other from a study that
identified colorectal cancer-specific WNT activation markers. Analysis of human
TCGA CRC datasets (COAD and READ) revealed that TDO2 gene expression
indeed correlates positively with WNT pathway activation signature genes (Fig. 8, BD). Correspondingly, tumor microarray analysis of human CRC samples showed
coincident increased signal for TDO2 and for nuclear β-catenin and c-Myc, which are
indicative WNT pathway activation (Fig. 10, A-E). We utilized iAP (APCmut/TP53mut)
and iKAP (inducible Krasmut with APCmut/TP53mut) (Boutin et al., 2017) murine
models for further validation. iAP GEMMs develop colorectal adenoma and/or
adenocarcinoma upon 4-hydroxytamoxifen (4-OHT) induction and iKAP mice
produce metastasis when KRAS mutation is induced by 4-OHT and Dox
administration. CRC tumors of iAP and iKAP mice showed that TDO2 expression
tracks closely with nuclear β-catenin and Ki67 signals in tumors (Fig. 11A).
Moreover, baseline TDO2 expression is slightly elevated in the small intestine
of ApcMin/+ mice relative to C57BL/6J WT controls (Fig. 11B), consistent with
haploinsufficiency for APC. Finally, ApcMin/+ small intestinal organoids and
CRISPR/Cas9-mediated APC-KO colon organoids showed significantly increased
TDO2 expression compared to APC-WT organoids (Fig. 11, C and D).
In contrast, another KP enzyme that has the same rate-limiting roles of KP as
TDO2, IDO1 did not exhibit mutual exclusive patterns with APC and CTNNB1
mutations in TCGA CRC nor correlate with WNT pathway activation (Fig. 12, A and
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B). We did not observe increase IDO1 expression in APC-deficient CRC tumors or
isogenic APC-KO cell lines. IDO2 expression exhibited a correlation with WNT
signaling, although its baseline expression level is extremely low (Fig. 12, A and C).
Collectively, APC-deficiency correlates with increased TDO2 expression in normal
and malignant intestinal epithelium in humans and mice.
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Figure 10: Upregulated TDO2 expression in human CRC TMA.
(A) IHC staining for b-catenin and TDO2 in CRC TMA slides. Dotted lines separate
high expression (below) and low expression (above) areas. Areas indicated by blue
and red boxes are shown in higher magnification. Scale bars, ´10 (200µm) and
´100 (20µm) (B) Representative images of IHC staining for TDO2 in human CRC
tumors with negative (n=34) and positive nuclear b-catenin (n=47). Scale bars, ×10
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(200µm) and ×40 (50µm). (C) CRC tumors with nuclear b-catenin showed higher
TDO2 expression (TDO2 staining score: 0-3). Pearson Correlation Coefficient
=42.342, ****P<0.0001. Chi-squared test. (D) Representative images of IHC staining
for c-Myc and TDO2 in human CRC TMA slide. Black arrows indicate low MYC/low
TDO2 regions and red arrows indicate high MYC/high TDO2 regions. Scale bars, ´4
(500µm) and ´40 (50µm) (E) Correlation analysis of quantified staining intensity of
TDO2 and c-MYC in CRC TMA. Chi-square value, df = 10.35, 2, **P<0.01, Chisquare test
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Figure 11: Upregulated TDO2 expression in mouse CRC tumors and
organoids.
(A) IHC analysis of CRC tumors from iAP and iKAP mice for nuclear b-catenin, Ki67,
and TDO2. Scale bar, 100µm for iAP and 500µm for iKAP. (B) IHC staining for
TDO2 in the small intestines from C57BL/6J wild-type and ApcMin/+ mice. Scale bars,
´10 (200µm) (C) Immunoblotting for TDO2 in small intestine organoids isolated from
C57BL/6J ileum and ApcMin/+ mice (D) Immunoblotting for TDO2 in wild-type and
APC-null colon organoids
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Figure 12: Analysis of IDO1/2 for mutual exclusive patterns with mutant APC
and correlation with WNT pathway in CRC.
(A) Mutual exclusive patterns of IDO1/2 to APC and CTNNB1 in TCGA CRC (COAD
+ READ, Provisional) dataset (n=220). (B) IDO1 mRNA expression is not correlated
with expression of WNT signature genes in TCGA CRC (COAD + READ,
Provisional) patients (n=433). n.s. P>0.05 (C) IDO2 mRNA expression shows
correlation with expression of WNT signature genes in TCGA CRC (COAD + READ,
Provisional) patients (n=433). **P<0.01
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3.2.3 APC deficiency upregulates TDO2 expression via transcription factor
TCF4
To validate the positive correlation between the expression of TDO2 and
WNT pathway activation in CRC cell lines, we generated multiple isogenic APC-KO
MC38 clones to compare CRC cells with APC wild type status to APC null cells and
confirmed the status of TDO2 expression (Fig. 13A). Each of the APC-KO clones
showed higher TDO2 expression relative to uncloned control cells and APC-WT
clones. Human WNT-inactive CRC cell line RKO and CRISPR/Cas9-mediated APCKO counterparts were also showed elevated TDO2 expression when APC is
deficient (Fig. 13B). TDO2 mRNA levels in the human and mouse CRC isogenic cell
lines corresponded to the TDO2 protein levels (Fig. 13C). In APC-WT RKO cells,
TDO2 expression was higher compared to a normal colon epithelial cells CCD-841CoN, but APC-KO showed significantly higher TDO2 expression (Fig. 13C).
Increased TDO2 mRNA levels upon APC deletion in isogenic prompted
examination of the human and mouse TDO2 gene promoter region for transcription
factors. We used the robust JASPAR database, which models transcription factor
DNA-binding preferences in multiple species for the analysis. JASPAR aligns
binding sites for transcription factors and generates a position frequency matrix
(PFM), in which the probability of each base at each position is calculated from the
alignment and this database provides scores which are based on the PFMs (Stormo,
2013). Upstream/promoter by 2kb and 5' UTR exons regions of human and mouse
TDO2 genes were scanned for WNT-related transcription factors, especially
TCF/LEF family. This analysis identified multiple binding sites for TCF7L2/TCF4 in
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the promoter region of TDO2 gene but failed to reveal prediction sites for other
TCF/LEF family members.
We further analyzed for evolutionarily conserved sites between human and
mouse by aligning two sequences and identified one conserved site. A conserved
WNT pathway transcription factor binding element for TCF4/TCF7L2 was identified
immediately upstream of the human and mouse TDO2 transcription start site (Fig.
14A). CHIP-seq analysis in the APC-KO MC38 cell line shows a positive peak
corresponding to the conserved TCF4 site in the promoter of TDO2 gene, but not
APC-WT, MC38 cells (Fig. 14B).
In the human APC-null DLD1 cell line, ChIP-PCR also documented TCF4 binding to
the promoters of TDO2 and the classical WNT target genes AXIN2 and MYC, but
not GAPDH promoter which served as a negative control (Fig. 14C). Furthermore, a
luciferase reporter driven by the human TDO2 promoter showed increased reporter
activity upon transduction of constitutively active β-catenin (CTNNB1 D90), which
mimics WNT pathway activation. (Fig. 14D). Conversely, dominant-negative TCF4
expression or TCF4 binding motif mutation abrogated reporter activity (Fig. 14, E
and F). Finally, TCF4 depletion or WNT inhibitor XAV-939 treatment, which
destabilizes β-catenin decreased TDO2 levels in multiple independent WNTactivated cells (Fig. 15, A-H). Thus, APC loss activates WNT-β-catenin resulting in
TCF4-mediated upregulation of TDO2 gene transcription.
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Figure 13: Increased TDO2 expression upon APC deletion in human and
mouse CRC cell lines.
(A) Immunoblotting of APC and TDO2 in uncloned MC38 cells, APC-positive clones,
and APC-deleted clones of MC38 cells (B) Immunoblots for TDO2 and b-catenin in
CRC cell lines RKO (human) and MC38 (Mouse) with their isogenic APC-KO
counterparts. (C) RT-qPCR shows APC-deleted RKO and MC38 cell lines exhibit
increased TDO2 mRNA expression. ****P<0.0001
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Figure 14: TCF4/TCF7L2 mediates upregulation of TDO2 in APC-mutated CRC
cells.
(A) DNA sequence binding motif for transcription factor TCF4/TCF7L2. Promoter
regions of human and mouse TDO2 gene harbor TCF4 binding motifs near
transcription starting site. The motif sequence is conserved in human and mouse
60

genes. (B) ChIP-seq in APC-WT and APC-KO MC38 cells showed binding peaks
for TCF4 on the promoters of TDO2 gene. (C) ChIP-PCR using TCF4 antibody
showed enriched binding to the promoter regions of TDO2 gene in DLD-1 cells.
GAPDH as a negative control; MYC and AXIN2 as positive controls. (D) Luciferase
activity of hTDO2 promoter in HEK 293T cells with constitutively active form of βcatenin (D90) with or without dominant negative (DN) TCF4. ***P<0.001. (E)
Luciferase activity of hTDO2 promoter in HEK 293T cells with constitutively active
form of β-catenin (D90) and dominant negative (DN) TCF4. ****P<0.0001. (F)
Luciferase activity of mutant TCF4 binding motif hTDO2 promoter in HEK 293T cells
with constitutively active form of β-catenin (D90) and dominant negative (DN) TCF4.
n.s.P>0.05
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Figure 15: Depletion of TCF4/TCF7L2 decreases TDO2 expression in APCmutated CRC cells.
(A-D) Immunoblots for TDO2 and TCF4 in APC-KO MC38 cell, HCT-15, and DLD-1
cell lysates after transfecting with siControl or three siTCF4s. Caco-2 cells were
infected with shControl or two different shTCF4 constructs. (E-H) Immunoblots for
TDO2 and b-catenin upon XAV-939 treatment in DLD-1, Caco-2, HCT-15, and iKAP
cell lines at indicated doses for 36hr.
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Chapter 4: Cancer cell autonomous signaling mediated by TDO2 in APCmutant CRC cancer
Content of this chapter is partly based on the following manuscript:
Lee R, Li J, Chakravarti D, Chen P, Li J., Wu C, Jiang S, LaBella KA, Spring DJ,
Wang YA, Zhao D., DePinho RA., Synthetic Essentiality of TDO2 in APC-Mutated
Colorectal Cancer, Submitted

4.1 Introduction and rationale
Inhibition or depletion of synthetic essential (SE) genes carry contextdependent vulnerabilities in cancers harboring specific tumor suppressor gene
mutations. SE genes can be initially identified by examining mutual exclusive
patterns in cancer genome data, which can be further triangulated with multiple other
datasets. Subsequently, potential SE genes should be validated using in vitro
experiments, in vivo models, expression profiles, and survival analysis. We identified
TDO2 as a prospective SE gene for mutated APC gene and its positive correlation
with Wnt signaling in CRC and other cancers. To validate whether TDO2 confers
specific sensitivity to CRC with mutant APC, we utilized CRISPR/Cas9-mediated
isogenic cell lines, intestinal organoid system and CRC and BRCA orthotopic mouse
models as well as TCGA cancer genomic database. Given the previously studied
roles of TDO2 in KP signaling and its downstream AhR pathway, we aimed to
understand the cancer cell-intrinsic mechanisms mediated by TDO2 and the
relationship between TDO2-AhR axis and mutant APC-driven upregulated Wnt
signaling in CRC.
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4.2 Results
4.2.1 TDO2 depletion specifically impairs growth and survival of APC/ WNTmutated CRC cells
To assess TDO2 essentiality as a function of APC status, the biological
impact of TDO2 depletion or pharmacological inhibition was tested across multiple
murine and human models. We utilized a human normal colon epithelial cell line
CCD-841-CoN and multiple CRC cell lines that have either wild type or mutated
APC/CTNNB1 genes (Fig. 16A). Using validated TDO2 shRNAs (Fig. 16B), we
found that TDO2 depletion had no impact on colony formation of human APC-WT
RKO cells yet impaired colony formation of isogenic CRISPR/Cas9-generated APCnull RKO controls (Fig. 16, C and D). Similarly, all human APC/CTNNB1-mutant
CRC lines (DLD1, HT-29, LS180, Caco-2) showed markedly reduced colony
formation upon TDO2 depletion (Fig. 16, C and D). Correspondingly, TDO2-specific
inhibitor 680C91 (Pilotte et al., 2012) treatment impaired the growth and survival of
APC-deficient but not APC-WT cancer cells including CCD-841-CoN cells (Fig. 16, E
and F).
In murine models, TDO2 depletion impaired the growth and cell death of
APC-null MC38 cells but not the parental APC-WT controls (Fig. 17, A-C).
Pharmacological inhibition of TDO2 showed increased sensitivity to 680C91 in APCKO MC83 cells compared to APC-WT cells (Fig. 17D). We generated dox-inducible
shTDO2 APC-WT and APC-KO MC38 cell lines and examined cell death upon
TDO2 depletion. Elevated cleaved caspase-3 was observed only in APC-KO cells
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but not in APC-WT cells (Fig. 17, E and F). Similarly, TDO2 depletion induced cell
death in cultured ApcMin/+ intestinal organoids (Fig. 17G).
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Figure 16: Depletion of TDO2 leads to impaired colony formation in human
APC-mutated CRC cells.
(A) Mutation Status of APC and CTNNB1 in human normal and CRC cell lines used
in this study. (B) RT-qPCR shows TDO2 shRNA knockdown efficiency in isogenic
APC-WT and APC-KO RKO as well as DLD-1, LS180, HT-29, and Caco-2 cell lines.
(C and D) Representative images and a quantification graph of colony formation
assay of human CRC cell lines expressing shControl and two shTDO2 constructs (E
and F) Representative images and a quantification graphs of colony formation assay
of human CRC cell lines upon 680C91 treatment at indicated doses for 48 hr.
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Figure 17: TDO2 depletion reduces colony formation ability and increases cell
death in murine APC-mutated CRC cells and organoids.
(A) RT-qPCR shows TDO2 inducible shRNA knockdown efficiency in APC-WT and
APC-KO MC38 cell lines. (B) Representative images of colony formation assay of
APC-WT and APC-KO MC38 cell lines expressing shTDO2. n=3 biological
replicates. (C) Quantification of Panel (D) Representative images of crystal violet
staining of APC-WT and APC-KO MC38 cell lines after treating 680C91 in a dosedependent manner for 48 hr. (E) RT-qPCR shows TDO2 inducible shRNA
knockdown efficiency in APC-WT and APC-KO MC38 cell lines. (F) Immunoblots of
cleaved Caspase-3 in APC-WT and APC-KO MC38 cell lines with ishTDO2 after
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doxycycline (Dox) treatment. (G) Immunoblots for TDO2 and cleaved Caspase-3 in
ApcMin/+ ishControl and ishTDO2 organoid cell lysates after Dox treatment for 48h.

70

4.2.2 TDO2 depletion specifically impairs tumor growth and survival of APC/
WNT-mutated CRC cells in vivo
In CRC orthotopic xenograft models that were established by cecal wall
injection, APC deletion in RKO cells showed accelerated tumor growth in vivo
compared to APC-WT RKO cells, which was expected observe considering the roles
of APC in activating WNT signaling and subsequent cell proliferation (Fig. 18A).
TDO2 depletion decreased growth of orthotopic APC-null RKO tumors in immune
deficient NSG mice but no tin APC-WT tumors (Fig. 18A). Similarly, TDO2 depletion
decreased growth of APC-null DLD-1 tumors which was rescued by enforced
expression of a hairpin-resistant TDO2 ORF (Fig. 18B). Pathological analysis of
these TDO2-depleted RKO and DLD-1 tumors revealed decreased cancer cell
proliferation (Ki67) and increased apoptosis (cleaved Caspase-3) (Fig. 18, C and D).
Rescuing the TDO2 expression in DLD-1 cells elevated Ki67 expression and
decreased apoptosis, indicating that TDO2 drives these cancer cell-intrinsic
hallmarks (Fig. 18D).
We performed similar experiments using immune competent C57BL/6J mice
and syngeneic MC38 cells to 1) examine whether murine CRC cells also show
impaired tumor growth in vivo and 2) investigate if immune responses are also
regulated by TDO2. Similar to the tumors in NSG mice, TDO2 depletion impaired
CRC orthotopic tumor growth (Fig. 19, A and B). Overall survival of mice was also
prolonged by TDO2 knockdown specifically in murine APC-KO MC38, but not APCWT controls (Fig. 19C). Immunohistochemistry staining of derived tumors showed
decreased cancer cell proliferation and increased cancer cell apoptosis (Fig. 19D).
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Interestingly, in immune-deficient mice, APC-KO MC38 tumors produced
similar survival curves to those in immune competent mice but showed reduced
survival benefit from induction of TDO2 depletion (Fig. 19E), consistent with cancer
cell intrinsic and immune modulatory roles for TDO2 specifically in APC-null cancers.
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Figure 18: TDO2 knockdown impairs tumor growth of human CRC cells in
vivo.
(A) Measured tumor weight in NSG mice injected with APC-WT and APC-KO RKO
cell lines expressing shControl or two shTDO2 constructs. Tumors were harvested
from at day 25 post- subcutaneous injection (n=7 per group) n.s.P>0.05,
****P<0.0001. two-tailed t-test. (B) Measurement of orthotopic tumor growth of TDO2
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knockdown and hairpin-resistant (HR) TDO2-ORF expressing DLD-1 cell lines in
nude mice (5´105 cells per injection). n = 5 per group. Total flux measurement of
tumors is shown. *P<0.05, two-tailed t-test. (C) IHC of Ki67 and caspase-3 in tumors
tissues generated from samples shown in panel (A). Scale bar, 100µm. (D) IHC of
Ki67 and caspase-3 in tumors tissues generated from samples shown in panel (B).
Scale bar, 100µm.
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Figure 19: TDO2 depletion specifically impairs growth of APC/WNT-mutated
murine CRC cells in vivo.
(A) Representative in vivo bioluminescence-based images of C57BL/6J mice at day
21 post-orthotopic injection of ishTDO2 APC-WT and APC-KO MC38 cell lines
(2×105 cells). Dox food was provided at day 5 after injection to induced TDO2
knockdown in vivo (n=5 per group). (B) Total flux measurement of tumors in panel
(A). n.s.P>0.05, *P<0.05 (C) Survival curves of C57BL/6J mice orthotopically
implanted with ishTDO2 APC-WT and APC-KO MC38 cell lines (2×105 cells). Dox
food was supplied at day 5 post-orthotopic injection to induce TDO2 knockdown in
n.s.P>0.05, **P<0.01, ***P<0.001. Log-rank (Mantel-Cox) test. (D) IHC of Ki67 and
caspase-3 in tumors tissues generated from samples in panel (A). Scale bar, 100µm
(E) Survival curves of NSG mice orthotopically implanted with ishTDO2 APC-WT
and APC-KO MC38 cell lines (2×105 cells). Dox food was applied at day 5 postorthotopic injection to induce TDO2 knockdown in vivo. n.s.P>0.05, ***P<0.001,
****P<0.0001. Log-rank (Mantel-Cox) test.
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The recent failure of the IDO inhibitor in clinical trials which tested the IDO1
inhibitor Epacadostat combined with anti-PD-1 in advanced melanoma patients
(Muller et al., 2019)

prompted us to compare the efficacy of TDO2 and IDO

inhibition. We tested the impact of TDO2 inhibition in our model system in vivo using
a small molecule TDO2 inhibitor. The recently developed validated TDO2 inhibitor
PF06845102/EOS200809 (Schramme et al., 2020) showed increased Trp and
decreased Kyn levels in serum when treated in mice via oral gavage. Interestingly,
the growth of tumors established with TDO2-overepxressing CT26 cells in Balb/C
mice were inhibited significantly when combined with anti-CTLA4 treatment
(Schramme et al., 2020).
TDO2 inhibitor was administrated by oral gavage to mice bearing APC-WT or
APC-KO MC38 orthotopic tumors twice daily and, consistent with the IDO inhibitor
failures, Epacadostat did not show anti-tumor activity in mice bearing either APC-WT
or KO MC38 CRC orthotopic tumors. TDO2 inhibitor treatment improved the survival
of mice bearing APC-KO MC38 tumors but not APC-WT controls despite their
inherently more malignant nature compared with parental APC-WT MC38 tumors
(Fig. 20A).
From a pharmacodynamic standpoint, histopathology showed that TDO2
inhibitor treatment decreased Ki67 and increased cleaved caspase-3 specifically in
the APC-KO MC38 tumors (Fig. 20C). Consistent with the IDO inhibitor failures, the
IDO inhibitor, Epacadostat, did not exhibit anti-tumor activity in mice bearing either
APC-WT or APC-KO MC38 CRC orthotopic tumors (Fig. 20, B and C).
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These results, together with the observation that the TDO2 inhibitor was well
tolerated (no signs of liver toxicity or weight loss), underscore the translational
potential of our work. In conclusion, these data support that TDO2 plays a prominent
role in supporting cancer cell survival and suppressing anti-tumor immunity
specifically in the setting of APC loss and WNT pathway activation.
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Figure 20: Anti-tumorigenic activity of TDO2 inhibitor specifically in APCdeficient CRC tumors.
(A) Survival curves of C57BL/6J mice orthotopically implanted with APC-WT and
APC-KO MC38 cell lines (2×105 cells). TDO2 inhibitor treatment (100mg/kg) was
initiated at day 5 post-injection twice a day by oral gavage. n.s.P>0.05, **P<0.01,
***P<0.001. Log-rank (Mantel-Cox) test.

(B) Survival curves of C57BL/6J mice

orthotopically implanted with APC-WT and APC-KO MC38 cell lines (2×105 cells).
Epacadostat (100mg/kg) was initiated at day 5 post-injection twice a day by oral
gavage. n.s.P>0.05, *P<0.05. Log-rank (Mantel-Cox) test. (C, D) IHC of Ki67 and
caspase-3 in tumors tissues generated from samples in panels (A) and (B). Scale
bar, 200µm.
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4.2.3 TDO2-Kyn-AhR axis supports APC-deficient cancer cell proliferation,
survival, and tumorigenic potential.
As noted previously, TDO2 mediates the first and rate-limiting step of KP that
metabolizes Trp to produce Kyn which in turn activates AhR to upregulate genes
governing myriad cellular functions. Gene Set Enrichment Analysis (GSEA) of RNAseq data from the isogenic APC-KO and APC-WT MC38 cell lines showed that Doxinduction of inducible shTDO2 decreased signatures of tryptophan metabolism as
well as xenobiotic metabolism, patterns consistent with the main functions of AhR
pathway (Fig. 21A). Correspondingly, expression of AhR and its target gene
CYP1B1 correlated positively with TDO2 levels in TCGA COAD dataset (Fig. 21B).
CRC tumors from iAP and iKAP also showed that AhR expression strongly tracks
with nuclear β- catenin and Ki67 (Fig. 21C) which is similar to TDO2. Moreover, the
APC-TDO2-KP connection was verified in the APC-KO MC38 model system via Kyn
ELISA by measuring Kyn concentration in the conditioned media harvested from the
APCmin organoids or cell lines. The ELISA analysis documented elevated Kyn
secretion relative to APC-WT controls (Fig. 21D) and TDO2 depletion in APC-KO
cells and ApcMin/+ organoids reduced Kyn levels (Fig. 21, D and E). Finally, gene
expression analysis with qRT-PCR showed upregulated AhR and its downstream
genes CYP1A1 and CYP1B1 in APC-KO MC38 cells compared to APC-KO MC38
cells, which was reversed upon TDO2 depletion in APC-KO MC38 cells and DLD1
cell lines (Fig. 21, F and G).
To validate Kyn and AhR in mediating TDO2-regulated biology in APC-KO
contetxt, we assayed the impact of Kyn treatment or AhR depletion in colony
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formation assays using the APC-KO MC38 ishTDO2 cell lines and APC-KO MC38
shAhR cell lines. In APC-KO MC38 cells, reduced colony formation upon induction
of TDO2 depletion or pharmacological inhibition (680C91) was partially rescued by
Kyn treatment (Fig. 22, A-E). In APC-WT MC38 cells, TDO2 inhibition and
supplementation of Kyn had no effect on the cell death (Fig. 22E). In the iKAP model
system, Kyn treatment to a cell line derived from iKAP tumors also decreased
680C91-induced cell death (Fig. 22F), further validating the cell autonomous activity
of theTDO2-AhR axis.
Finally, AhR depletion in APC-KO MC38 tumors resulted in increased survival
compared to the control tumors (Fig. 22G). Correspondingly, AhR-depleted APC-KO
MC38 tumors showed decreased proliferation (Ki67) and survival (Caspase-3) in the
cancer cells (Fig. 22H) as shown in TDO2-depleted APC-KO tumors. Together,
these findings are consistent with a key role for Kyn and AhR as mediators of TDO2
in APC-null cancer cell proliferation, survival, and tumorigenic potential.
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Figure 21: Upregulated TDO2 activates kynurenine pathway and AhR signaling
in APC-mutant CRC cells.
(A) GSEA graphs of Tryptophan metabolism and Xenobiotic metabolism with
alternatively expressed genes in TDO2 depleted APC-KO MC38 cells. Normalized
enrichment score (NES) and nominal P value are shown. (B) Positive correlation of
TDO2 expression to AhR and CYP1B1 expression in TCGA COAD database
(n=286). P values and R-squares value are shown. (C) IHC analysis for AhR in CRC
tumors from iAP and iKAP mice tracks with Ki67 and b-catenin staining. (D) Relative
kynurenine levels in ishTDO2 APC-WT and APC-KO MC38 cell lines upon TDO2
depletion. (E) Relative kynurenine levels in ApcMin/+ organoids infected with
ishControl and ishTDO2 constructs. (F) RT-qPCR shows TDO2 knockdown
decreased the expression of AhR downstream target genes in APC-KO MC38 cell
lines. ***P<0.001, ****P<0.0001. (E) RT-qPCR shows decreased expression of AhR,
CYP1B1 and CYP1A1 in DLD-1 shTDO2 cells compared to shControl cells.
****P<0.0001
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Figure

22:

TDO2-Kyn-AhR

axis

supports

APC-deficient

cancer

cell

proliferation, survival, and tumorigenic potential.
(A and B) Representative images and a quantification graph of colony formation
assay of ishTDO2 APC-KO MC38 cell lines after Dox alone or Dox/Kyn cotreatment. (C and D) Representative images and a quantification graph of colony
formation assay of ishTDO2 APC-KO MC38 cell lines after 680C91 alone or
680C91/Kyn co-treatment. € Immunoblots for cleaved Caspase-3 in APC-WT and
APC-KO MC38 cells treated with 680C91 alone or 680C91/Kyn co-treatment. (F)
Immunoblots for cleaved Caspase-3 in iKAP treated with 680C91 alone or
680C91/Kyn co-treatment. (G) Survival curves of C57BL/6J mice orthotopically
implanted with APC-KO MC38 cells with two different shAhR constructs (2×105
cells). ***P<0.001. Log-rank (Mantel-Cox) test. (H) Representation of IHC staining
for Ki67 and cleaved Caspase-3 in CRC orthotopic tumor tissues established with
shControl and shAhR #1 APC-KO MC38 cell lines. Scale bars, 100µm.
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4.2.4 TDO2-Kyn-AhR axis regulates glycolysis pathway of APC-mutant CRC
cancer cells.
To discern the cancer hallmarks regulated by TDO2, we performed the
pathway analysis using two different sets of samples to analyze the cell-autonomous
and immune pathways. Using RNA-seq data from APC-KO MC38 ishTDO2 cell lines
and tumor microarray datasets from the tumors established by the cell lines in
C57BL/6J mice were, we overlapped these pathways and further narrowed down the
list using the pathways that are upregulated by APC deletion to identify the pathways
regulated both by WNT pathway and TDO2.
GSEA was conducted on APC-KO MC38 cell lines and derivative tumors
following TDO2 depletion and consistent with known cancer cell intrinsic functions of
the APC/WNT pathway (Pate et al., 2014), hypoxia and glycolysis pathways were
up-regulated in APC-KO cells (Fig. 23, A and B). Correspondingly, APC-KO MC38
cells exhibited higher sensitivity to the GLUT1 inhibitor STF-31 than APC-WT
controls (Fig. 23C) and showed increased glucose uptake and lactate secretion,
which were reversed by TDO2 depletion (Fig. 23, D and E).
RT-PCR analysis confirmed up-regulation of key glycolysis genes (SLC2A1,
HK1/2, and PFKL), which were down-regulated upon TDO2 or AhR depletion (Fig.
24, A and B). Metabolite analysis of cell lysates and conditioned media from APCKO MC38 cells showed decreased levels of glycolysis pathway-related metabolites
upon TDO2 depletion (Fig. 24C). To further link TDO2 to the regulation of metabolic
pathways, we examined multiple elements in the GCN2 and mTOR pathways in
MC38 APC-WT and APC-KO cells containing an inducible shTDO2 construct (Fig.
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24D). APC deletion increased the level of phosphorylated eIF2, and this increase
was reversed upon TDO2 depletion in the APC null cells. In addition, TDO2
depletion decreased phosphorylated mTOR, only in the APC null cells.
We measured the modified glycolytic function induced by TDO2 via Seahorse
XF Glycolysis Stress Test analyses of MC38 APC-WT cells with empty versus TDO2
expression vectors (Fig. 25, A and B). Enforced TDO2 expression increased the key
parameters of glycolytic flux which are glycolysis, glycolytic capacity, glycolytic
reserve, as well as non-glycolytic acidification, relative to the MC38 empty vector
controls, reinforcing the role of TDO2 in promoting glycolysis (Fig. 25C). Finally, and
conversely, Seahorse experiments were performed on the MC38 APC-WT and APCKO ishTDO2 cells to assess the impact of TDO2 depletion on glycolytic flux in real
time. As expected, APC deletion was associated with increased glycolysis, glycolytic
capacity and glycolytic reserve only in the MC38 APC-KO lines (Fig. 25, D and E).
The most significantly changed parameter was glycolytic reserve, which shows ‘the
cell’s potential to respond to an energetic demand as well as how close the glycolytic
function is to the cell’s theoretical maximum’. Furthermore, the glycolytic flux was
also measured with MC38 APC-KO cells expressing two independent AhR shRNAs,
showing decreased overall flux upon AhR depletion (Fig. 25, F and G), again
confirming the metabolic regulatory role of the TDO2-AhR axis. Together, these
experiments show that TDO2-AhR signaling plays a key role in promoting cancer
cell glycolysis.
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Figure 23: Glycolysis pathway is increased by APC deficiency and decreased
by TDO2 depletion in MC38 cells.
(A) GSEA analysis (Hallmark gene sets) on genes that overlap between RNA-seq
datasets of ishTDO2 APC-KO MC38 cell lines (No dox vs. 48hr dox, n=3) and
microarray datasets of allograft tumors established with ishTDO2 APC-KO MC38
cell lines (No dox vs. dox treated, n=3). (B) GSEA correlation of glycolysis with
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altered gene expression in TDO2 depleted APC-KO MC38 cells. Normalized
enrichment score (NES) and nominal P value are shown. (C) Cell viability assay of
APC-WT and APC-KO MC38 cells treated with STF-31 for 24hr in a dose-dependent
manner. Six replicates per group. ***P<0.001, two-tailed t-test. (D) 2-DG uptake
assay with ishTDO2 APC-WT and APC-KO MC38 cell lines with and without dox
treatment. **P<0.01, ***P<0.001, two-tailed t-test. (E) Measurement of secreted
lactate with condition media from ishTDO2 APC-WT and APC-KO MC38 cell lines
with and without dox treatment. *P<0.05, **P<0.01, two-tailed t-test.
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Figure 24: TDO2-AhR axis regulates glycolysis pathway in APC-deleted MC38
cells.
(A) RT-qPCR analysis of glycolysis pathway genes in ishTDO2 APC-WT and APCKO MC38 cell lines. **P<0.01, ***P<0.001, ****P<0.0001, two-tailed t-test. (B) RTqPCR analysis of glycolysis pathway genes in APC-WT and APC-KO MC38 cell
lines expressing shControl or two shAhR constructs. *P<0.05, ***P<0.001,
****P<0.0001, two-tailed t-test. (C) Changes in concentration of key glycolysis
metabolites in ishTDO2 APC-KO MC38 cell line lysates. The red bars indicate cells
without dox treatment and the green bars indicate dox-treated cells. n = 5 per
biological replicates. (D) Western blot images of GCN2 and mTOR pathway
components in ishTDO2 APC-WT and APC-KO MC38 cells.
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Figure 25: Glycolytic flux is regulated by the TDO2-AhR axis.
(A) Representation of key parameters of glycolytic flux measured by Seahorse
experiment. (B and C) Measured extracellular acidification rate (ECAR) in MC38
Blank-ORF and mouse TDO2-ORF expressing cell lines. (D and E) Measured
extracellular acidification rate (ECAR) in MC38 APC-WT and APC-KO ishTDO2 cell
lines with and without Dox treatment. (F and G) Measured extracellular acidification
rate (ECAR) in MC38 APC-KO cell lines with shControl or two different shAhR
constructs (#1 and #2).
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Chapter 5: TDO2 regulates infiltration of tumor associated macrophage in
APC-mutated CRC.
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Chapter 5: TDO2 regulates infiltration of tumor associated macrophage in
APC-mutated CRC.
Content of this chapter is partly based on the following manuscript:
Lee R, Li J, Chakravarti D, Chen P, Li J., Wu C, Jiang S, LaBella KA, Spring DJ,
Wang YA, Zhao D., DePinho RA., Synthetic Essentiality of TDO2 in APC-Mutated
Colorectal Cancer, Submitted

5.1 Introduction and rationale
Immunosuppressive roles of kynurenine generated from KP signaling are
mediated by regulating functions of immune cells in the TME; activation and
recruitment of Tregs, inhibiting proliferation and effector functions of CD8-presenting
T cells, recruitment of MDSCs (Campesato et al., 2020, Liu et al., 2018, Takenaka et
al., 2019). However, whether the functions of KP signaling are at variance
depending on the genetic context of the tumor has not been studied.
Considering the low immune infiltration in CRC tumors, so called ‘cold
tumors’, and consequent disappointing efficacy of immunocheckpoint blockade
therapy in CRC, it is imperative to understand the signaling circuits that contribute to
immune evasive TME. Our comparative survival analysis with immune-compromised
NSG mice and B6 immuno-competent mice which were injected with isogenic APCWT and APC-Mut MC38 cell lines orthotopically alluded significant roles of immune
system in modulating TDO2-mediated tumor growth in APC-mutant CRC.
In addition, pathway analysis from both RNA-seq data from APC-KO MC38
ishTDO2 cell lines and tumor microarray datasets from the tumors established by
the cell lines in C57BL/6J mice showed several immune-related signaling as top
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modified pathways by TDO2 depletion, which prompted us to examine the immune
modulatory roles of TDO2.

5.2 Results
5.2.1 TDO2 depletion inhibits infiltration of tumor associated macrophages
Pathway analysis using RNA-seq data from APC-KO MC38 ishTDO2 cell
lines and tumor microarray datasets from the MC38 tumors established in C57BL/6J
mice showed, in addition to cancer cell-intrinsic processes, that APC status (APCKO versus APC-WT MC38) or TDO2 depletion in APC-deficient cancer cells and
tumors resulted in prominent representation of immune signaling signatures such as
TNFA signaling, inflammatory response, IL-6_JAK_STAT, allograft rejection, and
complement (Fig. 26, A and B). These in silico observations prompted
immunoprofiling of orthotopic tumors generated from isogenic APC-KO and APC-WT
MC38 cells with and without TDO2 depletion.
Cytometry by time of flight (CyTOF) analysis was performed using APC-WT
and APC-KO MC38 CRC orthotopic tumors developed in immunocompetent mice to
identify subsets of immune cells that are regulated by APC and TDO2. viSNE plots
of CyTOF data showed that APC deficiency resulted in significantly increased
macrophage abundance, which decreased upon TDO2 depletion (Fig. 26C).
Decreased macrophages by TDO2 depletion was not observed in APC-WT MC38
tumors, confirming the APC-deficient context specific immune responses regulated
by TDO2. We also observed changes in Tregs and neutrophils, but infiltration of
macrophages exhibited the most significant changes. Quantification of F4/80
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positive cells (total macrophages) and CD206high M2-like cells in CD45-positive
population confirmed enrichment of macrophages in APC-KO tumors and their
reduction upon TDO2 depletion (Fig. 26D). Immunohistochemistry staining of F4/80
and CD163 in these tumors aligned with the aforementioned CyTOF data (Fig. 27, A
and B). APC-WT and APC-KO MC38 orthotopic tumors treated with the TDO2
inhibitor PF06845102/EOS200809 were also examined for macrophage infiltration,
exhibiting similar results to the TDO2-depleted tumors. In contrast, Epacadostat
treatment did not increase infiltration of total and M2-like macrophages. (Fig. 27B).
Importantly, TDO2 inhibition also increased the number of infiltrating CD8-positive
cells only in APC-KO MC38 tumors, but Epacadostat-treated tumors showed no
changes in the number of CD8-expressing cells (Fig. 27, C and D), suggesting the
roles of TDO2 in adaptive immunity.
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Figure 26: TDO2 mediates tumor growth by regulating macrophage infiltration.
(A) GSEA analysis (Hallmark gene sets) on genes that overlap between RNA-seq
datasets of ishTDO2 APC-KO MC38 cell lines (No dox vs. 48hr dox, n=3) and
microarray datasets of allograft tumors established with ishTDO2 APC-KO MC38
cell lines (No dox vs. dox treated, n=3). The blue bars indicate immune responserelated pathways. (B) GSEA correlation of TNFA signaling and inflammatory
response with alternatively expressed genes in TDO2-depleted APC-KO MC38 cells.
Normalized enrichment scores (NES) and nominal P values are shown. (C) viSNE
analysis of F4/80+ and CD206+ immune cells assessed by CyTOF from CRC
orthotopic ishTDO2 APC-WT and APC-KO MC38 tumors. (D) Quantification of
macrophages (F4/80+) and M2 macrophages (CD206+) in tumors shown in panel
(C). CyTOF data were analyzed by FlowJo. Data represent mean ± s.d. *P<0.05,
**P< 0.01. two-tailed t-test.
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Figure 27: Increased macrophage infiltration mediated by APC deficiency is
reversed by TDO2 inhibition in MC38 tumors.
(A) Representation of IHC staining for F4/80 and CD163 in CRC orthotopic tumor
tissues established with ishTDO2 APC-WT and APC-KO MC38 cell lines. Scale
bars, 100µm. (B) Representation of IHC staining for F4/80 and CD163 in notreatment, TDO2 inhibitor-treated, and Epacadostat-treated APC-WT and APC-KO
MC38 CRC orthotopic tumor tissues. Scale bars, 200µm. (C and D) Representation
of IHC staining for CD8-positive cells in no-treatment, TDO2 inhibitor-treated, and
Epacadostat-treated APC-WT and APC-KO MC38 CRC orthotopic tumor tissues
with a quantification graph. Scale bars, 200µm.

102

5.2.2 TDO2 depletion inhibits infiltration of tumor associated macrophages in
human CRC
To corroborate TDO2-mediated TME modulation, specifically focusing on
macrophage infiltration and polarization, TCGA CRC datasets were examined for
correlation between the expression of macrophage (total and M2) and TDO2. It
showed that CRC tumors with high total and M2-like macrophage marker expression
is positively correlated with TDO2 expression (Fig. 28, A and B). Interestingly, Tregs
and MDSC markers also showed strong positive correlations between the degree of
TDO2 expression levels (Fig. 28, C and D).
This WNT-TDO2-macrophage correlation was further validated by human
CRC tumor microarray (TMA) analyses. Cancer cells with nuclear β-catenin signal
exhibited higher CD163 expression in the TME (Fig. 28E). Quantified data of the
stained CRC TME showed a significant positive correlation between nuclear βcatenin and infiltrated CD163-expressing/ M2-like macrophages (Fig. 28F).
Together, these findings support the model that activated WNT-driven upregulation
of TDO2 expression in turn activates the AhR network which functions to recruit
immune suppressive TAMs into the TME.
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Figure 28: TDO2 expression correlates with M2-like macrophage signature
expression.
(A - D) TDO2 mRNA expression is significantly correlated with expression of total
macrophage, M2 macrophage, regulatory T cells, and MDSC markers in TCGA CRC
(COAD + READ, Provisional) patients (n=433). ****P<0.0001. two-tailed t-test. (E)
Representative images of IHC staining for CD163 in human CRC tumors with
negative (n=42) and positive nuclear b-catenin (n=50). Scale bars, ×10 (200µm) and
×20 (100µm). (F) CRC tumors with nuclear b-catenin showed higher CD163
expression. Pearson Correlation Coefficient = 5.074, P =0.0243. Chi-squared test.
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5.2.3 TDO2 modulates TAM infiltration by regulating cytokines
To identify WNT-TDO2-AhR-regulated downstream factors that may recruit
TAMs into the tumor sites, we performed cytokine array profiling of conditioned
media (CM) from APC-KO MC38 ishTDO2 cells. Induction of TDO2 depletion
reduced secretion of classical macrophage cytokines including G-CSF, GM-CSF,
CXCL2 (Fig. 29A) and other cytokines (see below). Correspondingly, transwell
migration assays using bone marrow-derived macrophages (BMDM) showed that
CM from APC-KO MC38 ishTDO2 cultures increased macrophage migration which
was nullified upon TDO2 depletion (Fig. 29, B and C).
Next, to more fully vet the most highly regulated cytokines in our system, we
identified, and qRT-PCR validated the top ranked genes in the RNA-seq dataset and
found that CXCL5, CXCL7 (PPBP), CSF3 (G-CSF), CXCR2, CXCL2, CXCL10,
CCL2, and CXCL1 showed the most significant expression changes associated APC
deletion or TDO2 depletion (Fig. 30A). To further identify the target cytokines of
TDO2, cell lines that express ORFs of the top three genes from RNA-seq data -CXCL5, CXCL7 (PPBP), and CSF3 -- were generated in APC-KO MC38 ishTDO2
cells and monitored for tumor growth to identify genes that rescue the impaired
proliferation by TDO2 knockdown. Enforced expression of CXCL5, which showed
the highest fold changes, was most active in rescuing the decreased tumor growth
mediated by TDO2 depletion (Fig. 30B). Moreover, CyTOF analysis of CXCL5overexpressing APC-KO tumors showed increased TAMs in the presence of
shTDO2 (Fig. 30, C-E).
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Figure 29: Cytokines secreted from APC-deficient CRC cells promote
macrophage migration, which is inhibited by TDO2 knockdown.
(A) Cytokine array of condition media from ishTDO2 APC-KO MC38 cells with and
without dox treatment. The red boxes (labeled as 1-6) indicate cytokines that
significantly decreased after TDO2 knockdown. (B and C) Representation of
migrated BMDM cultured in condition media from APC-WT and APC-KO MC38 cell
lines expressing shControl or shTDO2. Scale bars, 50µm. The graph shows the
quantified data **P<0.01, two-tailed t-test.
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Figure 30: TDO2-AhR-CXCL5 axis regulates macrophage recruitment in APCmutated CRC tumors.
(A) Expression of immune response-related genes identified in RNA-seq analysis
and TDO2 were validated by RT-qPCR using ishTDO2 APC-WT and APC-KO MC38
cell lines. n=3 biological replicates. *P<0.05, ***P<0.001, ****P<0.0001. two-tailed ttest. (B) Volume of tumors established with ishTDO2 APC-KO MC38 cell lines
expressing Blank, CXCL5, CXCL7, and CSF3. Dox food was supplied at day 5 postorthotopic injection to induce TDO2 knockdown in vivo. n = 4 per group. n.s.P>0.05,
*P<0.05, ****P<0.001, ****P<0.0001. two-tailed t-test. (C) viSNE analysis of F4/80+
and CD206+ immune cells assessed by CyTOF from CRC orthotopic ishTDO2 APCWT and APC-KO MC38 tumors and CXCL5-ORF expressing APC-KO MC38 with
TDO2 depletion. (D and E) Quantification of macrophages (F4/80+) and M2
macrophages (CD206+) in tumors shown in (E). CyTOF data were analyzed by
FlowJo. Data represent mean ± s.d., n = 3 per group. *P<0.05, **P< 0.01. two-tailed
t-test.
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5.2.4 TDO2-AhR-CXCL5 modulates TAM infiltration and polarization in APCmutant CRC
To test whether CXCL5 can promote migration of macrophages, we
performed migration assays using recombinant CXCL5 proteins. APC-KO MC38
cells CM significantly promoted Raw 264.7 macrophage cell migration compared to
APC-WT CM and APC-KO TDO2-depleted CM decreased the migration (Fig. 31A).
Supplementing CXCL5 rescued macrophage recruitment when cultured with either
APC-WT and APC-KO CM. SX-682 is an inhibitor of CXCR1/2, where CXCL5 binds
and co-treatment of SX-682 abrogated the rescue by CXCL5 supplementation (Fig.
31A). Inhibiting CXCR1/2 not only blocks the binding of CXCL5 but also the binding
of other critical cytokines such as CXCL1-3, CXCL6, CXCL7, and CXCL8 that
mediates monocytes/macrophages infiltration as well (Olson and Ley, 2002). which
resulted in nullifying CXCL5 supplementation effects in APC-WT CM cultured
macrophage cells as well. In addition, AhR inhibitor treatment (CH223191)
profoundly decreased CXCL5 expression in APC-Wt and APC-KO MC38 cells in a
dose-dependent manner (Fig. 31B), which directly shows that CXCL5 expression is
regulated by AhR.
Moreover,

CM

from

APC-KO

MC38

cells

upregulated

several

M2

macrophage markers (CD206, YM1, YM2, Arg1) in Raw264.7 cells, which were
decreased by TDO2 knockdown and rescued by CXCL5 supplementation (Fig. 31C).
Similarly, BMDMs co-cultured with Kyn or CXCL5 showed increased M2
macrophage marker expression while CSF1 serves as a positive control.
Interestingly, CSF1 and CXCL5 did not increased the expression of a M1-like
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macrophage marker iNOS, Kyn upregulated iNOS expression in BMDM, which
suggests multi-faceted roles of Kyn in regulating monocyte education. These results
support a role for the TDO2-AhR axis in promoting TAM polarization (Fig. 31D).
Immunohistochemical analysis of total and M2-like macrophage markers
showed increased infiltration of macrophages in tumors with enforced CXCL5
expression despite the TDO2 depletion (Fig. 32A). Finally, allograft mice with APCKO MC38 cells showed increased survival upon TDO2 depletion (inducible shTDO2)
or

macrophage

depletion

by

Clodronate

liposomes

(Fig.

32B).

CXCL5

overexpression in APC-KO MC38 cell lines with TDO2 depletion significantly
shortened the survival of mice, which was reversed by depleting macrophages (Fig.
32B). Finally, APC-KO MC38 cells treated with anti-CXCL5 neutralizing antibody
also showed prolonged survival (Fig. 32C). These results suggest the roles of the
TDO2-AhR-CXCL5 axis in regulating TAM infiltration and polarization in APC-KO
CRC tumors.
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Figure 31: TDO2-AhR-CXCL5 axis regulates macrophage polarization.
(A) Representative images of migrated Raw264.7 cells cultured with ishTDO2 APCWT and APC-KO MC38 conditioned media in transwell assay. Recombinant CXCL5
protein (50 ng) and SX-682 (1 µM) were added to harvested conditioned media for
36 hr. Scale bar, 100 µm. n=3 biological replicates. Quantification: n.s.P>0.05,
***P<0.001, ****P<0.0001. two-tailed t-test. (B) RT-qPCR analysis for CXCL5
expression in APC-WT and APC-KO MC38 cells upon CH223191 treatment for 36hr.
***P<0.001 (C) RT-qPCR analysis of M2 macrophage signature genes in Raw264.7
cells incubated with conditioned media from ishTDO2 APC-WT and APC-KO MC38
cells for 30h. n=3 biological replicates. (D) RT-qPCR analysis of M2 macrophage
signature genes Arg1 and YM1 and M1 macrophage signature gene iNOS in BMDM
treated with CSF1 (50ng), CXCL5 (50ng), and Kyn (1mM) for 24hr n.s.P>0.05,
****P<0.0001. two-tailed t-test.
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Figure 32: Macrophage depletion or CXCL5 neutralization inhibit APC-deleted
tumor growth and improve survival.
(A) Representation of IHC staining for F4/80 and CD163 in CRC orthotopic tumor
tissues established with ishTDO2 and ishTDO2/CXCL5-ORF APC-KO MC38 cell
lines. Scale bars, 100µm. (B) Survival curves of C57Bl/6J mice orthotopically
implanted with ishTDO2 and ishTDO2/CXCL5-ORF APC-KO MC38 cell lines (5×105
cells). Clondronate liposomes or control Encapsome liposomes were given
intraperitoneally (100 µl) at day 2 post-orthotopic injection and three times a week.
(Encapsome and Clodronate groups, n = 6; Dox and Dox + Clodronate groups, n =
7; Dox + CXCL5-ORF + Encapsome, n = 5; Dox + CXCL5-ORF + Clodronate, n =
6). n.s.P>0.05, **P<0.01, ***P<0.001. Log-rank (Mantel-Cox) test. (C) Survival
curves of C57Bl/6J mice orthotopically implanted with APC-KO MC38 cell lines
(5×105 cells) treated with 200μg control rat IgG2b or neutralizing CXCL5 antibodies
every three days post injection. ****P<0.0001. Log-rank (Mantel-Cox) test.
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5.2.5 TDO2-AhR-CXCL5 in human TCGA datasets
To further validate the positive relationship between the TDO2-AhR-CXCL5
axis and TAM abundance in human CRC, TCGA CRC (COAD and READ) dataset
was clustered based on CXCL5 expression and analyzed for correlated immune
populations. These analyses revealed that TAM abundance correlated positively
with high CXCL5 expression (Fig. 33A). We also observed positive correlation
between CXCL5 expression and macrophage infiltration in TCGA BRCA dataset
(data not shown). Types of immune cells that showed positive correlation identified
macrophages as one of the immune cell subsets (Fig. 33B). Interestingly, T cell
showed the most significant positive correlation with CXCL5 expression level, further
suggesting the roles of CXCL5 in regulating adaptive immune responses in CRC.
In addition, CXCL5 expression correlated positively with increased tryptophan
metabolism (TDO2 as top pathway signature gene) and xenobiotic metabolism in
TCGA CRC (Fig. 33, C-E). Together, these data establish that TDO2-AhR signaling
upregulates CXCL5 which recruits TAMs to promote tumor growth; conversely,
neutralization of the TDO2-AhR-CXCL5 pathway is a validated anti-tumor strategy.
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Figure 33: CXCL5 expression is correlated with TDO2-AhR pathway and
macrophage infiltration in human CRC.
(A) GSEA correlation of macrophage populations with CXCL5-High tumors in TCGA
CRC database. NES and nominal P value are shown. (B) List of immune
populations positively correlated with CXCL5 expression in TCGA CRC (n = 254)
tumors. The red bar indicates macrophages. NES values are shown. (C)
Representative images of clustered TCGA CRC patient samples based on CXCL5
expression and expression of correlative top six tryptophan metabolism-associated
genes (TDO2, KYNU, KMO, IDO1, IL4I1, and AOX1) in ranked order (CXCL5 high, n
= 127, CXCL5 low, n = 127). (D and E) GSEA correlation of tryptophan metabolism
and xenobiotic metabolism with CXCL5-High TCGA CRC tumors. Normalized
enrichment score (NES) and nominal P value are shown.
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Chapter 6: A symbiotic relationship between APC-mutant CRC cells and tumor
associated macrophages
Content of this chapter is partly based on the following manuscript:
Lee R, Li J, Chakravarti D, Chen P, Li J., Wu C, Jiang S, LaBella KA, Spring DJ,
Wang YA, Zhao D., DePinho RA., Synthetic Essentiality of TDO2 in APC-Mutated
Colorectal Cancer, Submitted

6.1 Introduction and rationale
To further understand the role of CXCL5-recruited TAMs in regulating tumor
growth, we considered the possibility that, in addition to their classical
immunosuppressive functions, infiltrating macrophages may also provide trophic
support for cancer cells as we have recently reported in GBM (Chen et al., 2019). To
that end, we examined the receptors on APC-KO cells that bind to macrophagederived ligands which may promote cancer cell growth. From a phospho-tyrosine
kinase (RTK) receptors assay, we identified that Axl and Gas6 plays an important
role in promoting heterotypic interactions between tumor cells and infiltrated tumorassociated macrophages.
Axl is one of the members of TAM RTKs which are consisted of Tyro3, Axl
and Mer. Their ligands include Gas6 and Protein S. When Gas6 binds to Axl, Axl
gets phosphorylated and mediates proliferation and migration through multiple signal
transduction including MAPK, NOTCH, PI3K pathways (Brown et al., 2016). Axl is
over-expressed in many types of cancer and its expression is associated with
metastasis and adverse prognostic factor. Previous findings on Gas6 showed that it
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is expressed abundantly in macrophages and DC, especially in tumor context. And
treatment of Gas6 to cancer cells promoted proliferation (Loges et al., 2010). They
showed that tumor cells can program the infiltrating monocytes to produce Gas6
which accelerates the tumor growth (Loges et al., 2010).

6.2 Results

6.2.1 GAS6 is upregulated by CXCL5 in macrophages and promotes cancer
cell growth
To further understand the role of CXCL5-recruited TAMs in regulating tumor
growth, we hypothesized that in addition to their classical immunosuppressive
functions, infiltrating macrophages may also provide some trophic support for cancer
cells. We examined the receptors on APC-KO cells that bind to macrophage-derived
ligands which may promote cancer cell growth. Receptor tyrosine kinase phosphoarray analysis revealed increased phosphorylated Axl in APC-KO cells which was
decreased upon TDO2 depletion only in the APC-KO cell lines (Fig. 34A).
Gas6 is a ligand of the Axl receptor tyrosine kinase and secreted mainly by
TAMs in the TME (Loges et al., 2010). To assess whether macrophage-derived
Gas6 might activate Axl to support the growth of APC-deficient cancer cells, we first
validated that orthotopic APC-KO MC38 tumors showed increased phosphorylated
Axl in cancer cells (indicated by EpCam staining) which was reduced upon TDO2
depletion and rescued upon enforced CXCL5 expression in TDO2-depleted APC-KO
MC38 tumors (Fig. 34B).
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6.2.2 Kyn and CXCL5 upregulate GAS6 in macrophages and polarize them into
M2 macrophage phenotype
We evaluated whether secreted factors from cancer cells might amplify Gas6
expression in macrophages by utilizing mouse BMDMs. BMDMs were incubated
with conditioned media from MC38 cell lines and the expression of Gas6 were
measured with qRT-PCR. Conditioned media from APC-KO MC38 cell lines
significantly increased the Gas6 mRNA levels in macrophages compared to APCWT cell lines (Fig. 34C). TDO2 depletion in APC-KO MC38 cells resulted in
decreased Gas6 expression in BMDMs (Fig. 34C).
In addition, while CSF1 is known to upregulate Gas6 in macrophages (serves
as a positive control) (Loges et al., 2010), Kyn and CXCL5 also increased Gas6
expression in BMDM. Interestingly, the Gas6 itself also increased the Gas6
expression in macrophages, suggesting establishment of a positive feedback loop
between cancer cells and macrophages. (Fig. 34D).
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Figure 34: APC-deficient CRC cells promote macrophage-derived Gas6, which
binds to Axl on tumor cells.
(A) Mouse RTK phospho-array of lysates from ishTDO2 APC-WT and APC-KO
MC38 cell lines before and after dox treatment. The red box indicates Axl. (B)
Immunofluorescence staining of phosphorylated Axl (RFP) in CRC orthotopic tumors
established by injecting APC-WT and APC-KO MC38 cells into C57BL/6J mice.
Epithelial cells are stained with EpCam and indicated by GFP. Blue is DAPI staining.
×63 magnification. (C) RT-qPCR analysis of Gas6 expression in BMDM cultured in
conditioned media from ishTDO2 APC-WT and APC-KO MC38 cell lines. n=3
biological replicates. n.s.P>0.05, ****P<0.0001. two-tailed t-test. (D) RT-qPCR
analysis of Gas6 expression in BMDM treated with CSF1 (50 ng), Kyn (1 mM),
CXCL5 (50 ng) and Gas6 (25 ng) for 24 hr. n=3 biological replicates. ****P<0.0001.
two-tailed t-test.
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6.2.3 Depletion of Gas6 in macrophages impairs tumor growth in vivo
Finally, to validate the roles of Gas6 in promoting tumor growth in vivo, we
first established shGas6 Raw 264.7 macrophage cell lines with two independent
shRNAs (Fig. 35A). CT26 murine CRC cell lines were utilized for the co-injection
experiments in order to match the origin of mouse strain (BalB/cJ) for Raw 264.7
cells. shControl and shGas6 macrophage cells and CT26 tumor cells were coinjected into syngeneic BalB/cJ mice and tumor burden was measured which
showed that the mice injected with Gas6-depleted macrophages showed reduced
tumor growth (Fig. 35B),
Reversely, macrophages pre-treated with recombinant CXCL5 proteins
before the injection promoted the growth of CT26 cells significantly (Fig. 35C).
Collectively, these data reveal a symbiotic heterotypic signaling circuit between
cancer cells and macrophages mediated by the CXCL5-Gas6-Axl axis.
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Figure 35: Gas6 secreted by macrophages promotes tumor growth.
(A) RT-qPCR shows GAS6 shRNA knockdown efficiency in Raw264.7 cells. n=3
biological replicates. ***P<0.001. two-tailed t-test. (B) Representative in vivo
bioluminescence-based images of BalB/CJ mice at day 20 post-orthotopic coinjection of CT26 cells (1×105 cells) and macrophage cell line Raw264.7 (1×105
cells) with shControl or shGAS6. Total flux measurement of the end point. **P< 0.01.
two-tailed t-test. (C) Representative in vivo bioluminescence-based images of
BalB/CJ mice at day 20 post-orthotopic co-injection of CT26 cells (1×105 cells) and
macrophage cell line Raw264.7 (1×105 cells) pre-treated with 100 ng of CXCL5 for
48 h before injection. Total flux measurement of tumors was done at the end point.
**P< 0.01. two-tailed t-test.
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7.1. Conclusions and discussion
In this study, we performed the first large-scale genome analysis to identify
SE genes for APC mutations, which are found in the vast majority of CRC patients
and play a critical role in initiating tumorigenesis. Using synthetic essentiality as a
conceptual framework, genomic loss-of-function analyses identified TDO2 as a key
downstream effector specifically for APC-deficient cancers. Increased TDO2
mediates kynurenine pathway (KP) and generates excessive Kyn, which activates
AhR pathway. We established that TDO2-Kyn-AhR axis increases the dependency
of APC-null CRC cells on glycolysis and promotes cancer cell proliferation and
growth. The axis also drives expression of CXCL5 which promotes recruitment of
immune suppressive TAMs into the TME. These TAMs also secret Gas6, which
binds to Axl expressed on the cancer cells to further promote proliferation and
growth of cancer cells, forming a synergistic interaction between cancer cells and
TAMs (Fig. 36).
The functions of TDO2 have been studied primarily in the context of
neurological diseases due to its expression in neuronal tissues and its roles in
neurotransmitter production. Recent studies have revealed TDO2 overexpression in
multiple cancer types and its role in facilitating tumorigenic signaling via KP
(D'Amato et al., 2015)(D'Amato et al., 2015; Ott et al., 2015; van Baren and Van den
Eynde, 2015). Another key KP enzyme IDO1 is also highly expressed in various
tumors and is known to suppress anti-tumor immunity. However, IDO1 was not a
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Figure 36: Working model
APC-deficiency activates a TCF4-TDO2-AhR-CXCL5-GAS6-AXL circuit that impacts
multiple cancer hallmarks and immune responses.
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critical dependency for APC-deficient CRC cells which suggests non-redundant,
context-specific roles of these two key KP enzymes; moreover, TDO2 and IDO1 are
differentially regulated (i.e. AhR can transcriptionally regulate IDO1 but not TDO2)
(Puccetti, 2014). In addition to known transcriptional regulatory mechanisms
governing TDO2 activity include hemes and glucocorticoid hormones (Badawy,
2017), our studies revealed that the WNT transcription factor TCF4 can upregulate
TDO2, but not IDO1, expression in APC-deficient CRC cells. Specifically, AhR can
regulate IDO1, but not TDO2, expression (Puccetti, 2014). In contrast, transcriptional
regulatory mechanisms governing TDO2, but not IDO1, expression include hemes
and glucocorticoid hormones (Badawy, 2017), as well as the WNT transcription
factor TCF4 specifically in APC-deficient CRC cells (this study).
Our findings showing that TDO2-Kyn-AhR axis regulates glycolysis as a
cancer cell intrinsic mechanism are consistent with previous findings that AhR can
directly regulate genes involved in energy metabolism such as lipid and cholesterol
synthesis (Gabriely et al., 2017). In APC-deficient CRC, we established that AhR
regulates glucose uptake and overall glycolytic flux by regulating glycolysis genes
including SLC2A1, HK1/2, PFKL, LDHA, and ALDOA. Experimentally, we showed
knockdown of TDO2 and AhR downregulated those genes in APC-mutant cells.
Tumor cell glycolysis pathway is directly targeted in t APC-deficient CRC tumor cells,
we analyzed the expression of multiple glycolysis-related genes (GO Biological
Process-Glycolysis Geneset) in the TCGA COAD dataset using the Oncomine
platform. Colon adenocarcinoma which shows significantly lower APC expression as
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expected (relative to normal colon and cecum) exhibits higher expression of
glycolytic genes.
Importance of KP and AhR signaling in regulating tumor immunity is wellestablished in the context of both physiological and pathological conditions. In mice,
AhR is critical for function and maintenance of innate T cells in the the
gastrointestinal tract (Stange and Veldhoen, 2013). In stress conditions, whole body
knockout of AhR exhibit impaired differentiation and function of T helper 17 cells and
regulatory T cells to environmental toxins (Quintana et al., 2008, Stange and
Veldhoen, 2013). In cancer, previous studies of AhR support both pro- and antitumorigenic roles. Whole body knockout of AhR in APCmin mice resulted in
increased cecal tumors and no change in small intestinal tumors (Kawajiri et al.,
2009), underscoring the context-specific actions of AhR in cancer. This may relate to
1. Non-ligand dependent roles of AhR such as degradation of b-catenin, 2. Effects of
Ahr on non-cancer cell types, 3. Tissue-specific biology. Different cancer types,
regulatory mechanisms for AhR by its modulators such as ARNT, HSP90, XAP2,
diverse agonists/antagonists, and direct immune modifying roles of AhR both in
cancer cells and immune cells could be accounted for the discrepancy.
Here, we identified tumor-promoting roles of AhR in the context of APCmutant context mediated by APC-TCF4-TDO2-AhR pathway and infiltrated immune
cells. In mice, whole body knockout of AhR exhibit impaired differentiation and
function of T helper 17 cells and regulatory T cells to environmental toxins (Quintana
et al., 2008, Stange and Veldhoen, 2013). AhR is also critical for function and
maintenance of innate T cells in the the gastrointestinal tract (Stange and Veldhoen,
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2013). However, previous studies on AhR support both its pro- and anti-tumorigenic
roles. Whole body AhR knockout in APCmin mice developed more cecal tumors
(Kawajiri et al., 2009), suggesting ligand-independent roles of AhR which is
degradation of b-catenin. Different cancer types, regulatory mechanisms for AhR by
its modulators, diverse agonists/antagonists, and immune modifying roles directly by
AhR both in cancer cells and immune cells could be accounted for dual roles of AhR.
Beyond the known immune suppressive activity of TAMs, our work revealed a
role for TDO2 in supporting the growth of cancer cells in vivo. Specifically, we
observed that, while TDO2 depletion in APC-null cancer cells show a profound
decrease in phosphorylated Axl in tumors in vivo, pointing to increased Gas6
availability in the TME compared with cell culture settings. We determined that TAMs
represent a major source of Gas6 compared with all other tumor-infiltrating
immunocytes; moreover, macrophages derived from bone-marrow or peripheral
blood do not express Gas6 (Loges et al., 2010). Activated Axl promotes diverse
cellular processes including cancer cell survival via AKT, proliferation, EMT,
migration, and invasion (Gay et al., 2017). Our cytokine rescue experiment data
showed complete rescue by enforced expression of CXCL5 upon TDO2 depletion in
APC-KO cells (Fig. 30B), suggesting tumorigenic functions of Gas6/Axl contribute to
cancer cell growth. Moreover, Gas6/Axl can stabilize b-catenin (Jin et al., 2017),
which enables cancer cells and TAMs to form a reinforcing paracrine loop. In
pancreatic and ovarian cancer models, inhibition of Gas6/Axl pathway combined
with chemotherapies has been shown to be synergistic (Kariolis et al., 2017).
Correspondingly, previous work in GBM models has shown that combined Axl
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inhibitor and immune checkpoint blockade inhibitor treatment showed better antitumor activity (Sadahiro et al., 2018).
Our human CRC profile analysis corresponds well with our murine findings,
showing positive correlation between TAM abundance and TDO2 expression levels.
In CRC, pro-tumorigenic TAMs are known to support tumor progression and limit the
efficacy of immunotherapy (Peranzoni and Donnadieu, 2019, Pathria et al., 2019, Liu
and Cao, 2015). In glioblastoma, Kyn produced by glioma cells has been shown to
recruit TAMs by binding to AhR and promote CD8 T cell dysfunction via expression
CD39 in TAMs (Takenaka et al., 2019). Analysis of recent failed clinical trial
targeting IDO1 with Epacadostat in combination with anti-PD1 antibody in melanoma
showed that immune checkpoint blockade, BRAF inhibitors, and chemotherapy
serves to upregulate IDO1 expression which may overcome coverage by the IDO1
inhibitor dose used. Studies also showed that cancer cells upregulate ABC
transporters which might further reduce the availability of IDO1 inhibitor in the TME.
Our findings expand the list of possibilities of compensatory mechanisms. We
speculate that TDO2 upregulation could serve to sustain the Trp metabolism and
KP-AhR pathway despite the IDO1 inhibition, underscoring the importance of
understanding the tumorigenic roles of TDO2 and the genotypic context in which it
operates (Opitz et al., 2020). In conclusion, identifying synthetic essential genes in
CRC harboring APC deficiencies will improve the understanding of CRC tumor
initiation and also pave the way for developing new treatment strategies for this
intractable cancer.
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7.2 Future directions
Considering the roles of TDO2 in regulating immune responses in APC-KO
tumors, identifying optimal combination therapies of TDO2i and immune checkpoint
inhibitors (ICIs) to improve the treatment of CRC would be in great importance.
Using the iKAP model, engineered with inducible Kras oncogenic mutation (KRAS*)
activating model and loss of APC and p53, provides an ideal platform for studying
the combination treatment with TDO2i, since iKAP spontaneous tumors mirror the
natural tumor incidences in CRC patients and iKAP tumors develop more
aggressively. Assessing T cell checkpoint in iKAP CRC tumors under TDO2 inhibitor
treatment with single cell sequencing or immunohistochemistry would allow us to
gain insights on which immune-modulatory molecules should be intervened with
TDO2.
Functions of infiltrated TAMs in APC-KO tumors could be further assessed in
the context of T cell suppressive functions. Limitations in dividing macrophage
populations into M1 and M2-like macrophages have been reported, showing the
complex and reversible nature of macrophage subtypes. Transcriptomic analysis of
infiltrated macrophages in CRC tumors and investigating whether their gene
expression patterns, or states change by different APC status, TDO2 depletion, or
Kyn supplementation would be greatly informative for deeper understanding of
macrophage biology.
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